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Abstract 
 
Susan Kim Conroy 
 
CHEMOTHERAPY, ESTROGEN, AND COGNITION: NEUROIMAGING AND 
GENETIC VARIATION 
 
The time course and biological mechanisms by which breast cancer (BC) and/or 
alterations in estrogen status lead to cognitive and brain changes remain unclear. 
The studies presented here use neuroimaging, cognitive testing, genetics, and 
biomarkers to investigate how post-chemotherapy interval (PCI), chemotherapy-
induced amenorrhea (CIA), and genetic variation in the estrogen pathway affect 
the brain. Chapter 1 examines the association of post-chemotherapy interval 
(PCI) with gray matter density (GMD) and working memory-related brain 
activation in BC survivors (mean PCI 6.4, range 3-10 years). PCI was positively 
associated with GMD and activation in the right frontal lobe, and GMD in this 
region was correlated with global neuropsychological function. In regions where 
BC survivors showed decreased GMD compared to controls, this was inversely 
related to oxidative DNA damage and learning and memory scores. This is the 
first study to show neural effects of PCI and relate DNA damage to brain 
alterations in BC survivors. Chapter 2 demonstrates prospectively, in an 
independent cohort, decreased combined magnitudes of brain activation and 
deactivation from pre-to post-chemotherapy in patients undergoing CIA 
compared to both postmenopausal BC patients undergoing chemotherapy and 
healthy controls. CIA’s change in activity magnitude was strongly correlated with 
change in processing speed, suggesting this activity increase reflects effective 
cognitive compensation. These results demonstrate that the pattern of change in 
brain activity from pre- to post-chemotherapy varies according to pre-treatment 
menopausal status. Chapter 3 presents the effects of variation in ESR1, the gene 
that codes for estrogen receptor-α, on brain structure in healthy older adults. 
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ESR1 variation was associated with hippocampus and amygdala volumes, 
particularly in females. Single nucleotide polymorphism (SNP) rs9340799 
influenced cortical GMD and thickness differentially by gender. Apolipoprotein E 
(APOE)-ε4 carrier status modulated the effect of SNP rs2234693 on amygdala 
volumes in women. This study showed that genetic variation in estrogen relates 
to brain morphology in ways that differ by sex, brain region and APOE-ε4 carrier 
status. The three studies presented here explore the interplay of BC, estrogen, 
and cognition, showing that PCI, CIA, and ESR1 genotype influence brain 
phenotypes. Cognitive correlates of neuroimaging findings indicate potential 
clinical significance of these results.  
 
Brenna C. McDonald, PsyD, MBA, Chair  
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1 
Introduction 
Breast cancer and cognition 
Breast cancer (BC) will affect 1 in 8 American women, and the 5-year survival 
rate is 90% as of 2009 [1]. BC patients undergo many treatments, including 
surgery, cytotoxic chemotherapy, targeted therapies, radiation and hormonal 
treatments. As survivorship continues to increase, attention to the impact of BC 
and its treatments on patients’ quality of life grows. Cognitive effects have been a 
recent area of focus. Post-chemotherapy neuropsychological deficits, observed 
in 13-70% of survivors [2], are subtle, typically occur in executive function, 
processing speed, and memory domains, and may persist for many years (for 
review and meta-analysis see [3-6]). Lower than expected cognitive performance 
has also been described in cancer patients before any treatment is initiated [7, 8], 
suggesting that host factors and the disease process itself also play a role. 
Subjective cognitive changes have also been reported in a range of studies, and 
interestingly are not highly correlated with objectively measured 
neuropsychological dysfunction (see [9] for review).  
 
Several mechanisms have been proposed for cancer- and treatment-related 
cognitive dysfunction [10]. Chemotherapeutic agents increase oxidative stress, 
induce DNA damage, and may lead to decreased telomere length. Genetic and 
cancer- or treatment-induced alterations of blood-brain barrier integrity may 
influence the amount of direct neurotoxicity caused by chemotherapy. Genetic 
predisposition may leave some patients more vulnerable to (or less able to 
recover from) neural insult. The changes that occur in the body as a result of 
cancer and its treatments are complex. Systemic inflammation and changes in 
neuroendocrine activity and the interaction of these processes with the brain 
have been associated with neuropsychological and psychosocial dysfunction in 
cancer patients [11-13]. Increases in inflammatory processes increase overall 
oxidative stress. Dysregulation of cytokines and inflammatory processes may 
result from either cancer or treatment. For example, patients show increased 
serum levels of a protein associated with the inflammatory cytokine tumor 
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necrosis factor (TNF)-α one month post-chemotherapy [14]. Some cancer 
treatments directly or indirectly alter levels of hormones that are known to affect 
cognition, including estrogen and testosterone. All of these potential 
mechanisms, and possibly others, may combine in varying proportions to cause 
cognitive dysfunction in an individual cancer patient.  
 
Study of animal models has yielded valuable insights (see [15] for review). Rats 
with induced mammary tumors show increased hippocampal expression of the 
cytokines interleukin (IL)-1β, IL-6, IL-10, and tumor necrosis factor (TNF)-α in the 
absence of any cancer treatment [16]. Oligodendrocytes and their precursors 
appear to be particularly vulnerable, and delayed myelin damage has been 
observed following several types of chemotherapy [17, 18]. Methotrexate 
treatment decreases hippocampal neurogenesis and alters hippocampal 
vasculature in rats without outright cell death 12 weeks post-treatment regardless 
of tumor presence or absence [19-21]. Cyclophosphamide appears to impair 
long-term potentiation (LTP) during treatment, with some post-treatment recovery 
[22]. Cerebellar cells show alterations in cytoskeletal and calcium regulating 
proteins and cortical cells show dendritic retraction in response to cytosine 
arabinoside (AraC) treatment [23, 24].  
 
Neuroimaging of cancer- and treatment-related changes 
Neuroimaging is a valuable tool in the assessment of neural effects of cancer 
and its treatments. Neuroimaging of chemotherapy-related cognitive dysfunction 
has several potential uses, including providing biomarkers for future identification 
of patients at risk and stimulating hypotheses for basic science investigations 
which could ultimately lead to neurorehabilitative or neurotherapeutic agent 
development. Further, imaging may detect alterations that are not evident in 
neuropsychological testing, as the subtlety of cancer and treatment effects on 
cognition often lead to neuropsychological test scores in the normal range. The 
most important research tool for structural imaging to date has been anatomic 
magnetic resonance imaging (MRI). For gray matter (GM), a technique called 
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voxel-based morphometry (VBM) is often employed in analyzing MR images. 
VBM is a non-biased, fully automated technique that can assess density within a 
tissue compartment (GM, white matter (WM), or cerebrospinal fluid (CSF)) 
throughout the brain. VBM and other voxel-by-voxel comparisons with other 
imaging modalities typically utilize statistical parametric mapping (SPM), a 
method which calculates statistical differences between groups and/or over time 
at each voxel in the brain, with both peak magnitude and spatial extent (number 
of voxels) considered in determining statistical significance of a particular cluster 
[25]. White matter analyses have utilized diffusion tensor imaging (DTI), to 
assess both magnitude and directionality of water diffusion (see [26] for review). 
As water flows preferentially along the direction of myelinated WM tracts (as 
opposed to orthogonally), DTI allows assessment of WM tract integrity, which 
can be disrupted in many neurological disorders.  
 
Functional imaging has employed both positron emission tomography (PET) and 
functional MRI (fMRI). PET imaging relies on the injection of trace amounts of a 
radioactive compound to assess a particular aspect of brain function at rest or 
during activity. For example, the most commonly used tracer, (18F)-
fluorodeoxyglucose [(18F)-FDG], a glucose analog, is used to assess regional 
brain metabolic activity, while (15O)-H2O is used to measure changes in blood 
flow. Blood oxygenation level dependent (BOLD) (fMRI) is a noninvasive (i.e., 
contrast-free) method used to detect regional brain activation in response to 
presentation of a stimulus or performance of a cognitive task. During a particular 
cognitive function, a characteristic anatomical pattern of activation is observed as 
task-related areas of the brain become more active. At the same time, regions of 
the default mode network (DMN) are deactivated in a complementary process as 
neural resources are reallocated [27]. Magnitudes of both activation and 
deactivation increase parametrically with task difficulty [28, 29]. Activated brain 
regions show increased blood flow, peaking about five seconds after stimulus 
presentation. This increase in blood flow is called the hemodynamic response, 
and locally increases the amount of deoxyhemoglobin present; deoxyhemoglobin 
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is paramagnetic and perturbs the magnetic field, thus serving as an endogenous 
contrast agent for detecting neuronal activity [30]. Pathology can manifest as 
compensatory hyperactivation or failure to activate sufficiently, as illustrated by 
the early, higher functioning or later, lower functioning stages of mild cognitive 
impairment (MCI), respectively [31, 32]. Thus, association of fMRI alterations with 
neurocognitive performance and self-reported cognition is important in 
interpretation of results.  
 
Structural studies have revealed brain changes in GM in BC patients. Two recent 
prospective studies in independent cohorts from our laboratory [33, 34] have 
shown relatively decreased GM density, particularly in the frontal lobes, in BC 
patients undergoing chemotherapy from pre-treatment to one month post-
chemotherapy completion compared to both BC patients not receiving 
chemotherapy and healthy controls. Interestingly, one report showed a 
relationship between change in self-reported executive function and change in 
GM density [34]. No clinically meaningful differences among these three groups 
were evident at baseline in either study. One study followed patients a year later 
and found that GM density partially recovered but did not return baseline levels 
[33]. Retrospective studies have shown longer-term changes in GM. The first 
retrospective VBM study of chemotherapy effects showed diffusely distributed 
decreases in cortical GM in cancer survivors at least five years post-treatment 
compared to healthy controls [35]. Another study demonstrated decreased frontal 
and medial temporal GM in chemotherapy-treated BC patients an average of 4 
months post-treatment compared to non-chemotherapy-treated patients, and GM 
in these regions was correlated with attention and memory measures. In a 
somewhat overlapping cohort, no differences were present an average of 2.6 
years post-chemotherapy [36]. Nine years post-treatment, BC survivors exposed 
to chemotherapy showed decreased GM in posterior parietal and cerebellar 
regions compared to non-chemotherapy-treated BC survivors [37], while 
survivors an average of 21 years post-treatment showed a decrease in total GM 
volume but no focal decreases evident on VBM compared to cancer-free controls 
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[38]. In summary, chemotherapy appears to negatively affect GM, most 
prominently in the frontal lobes, with effects that are most pronounced in the 
months following chemotherapy. These effects have been associated with both 
subjective and objective cognitive function. Partial GM recovery appears to occur 
in the following years to decades. Pre-treatment GM differences between BC 
patients and controls have not been apparent.  
 
Several studies have also explored treatment-related changes in WM. A single 
prospective DTI study has shown decreased white matter integrity from pre- to 3-
5 months post-chemotherapy in BC patients. Non-chemotherapy-treated patients 
and healthy controls did not show changes over time, and there were no 
differences between the three groups at baseline. Interestingly, frontal WM 
change was associated with change in verbal memory score, and parietal WM 
change was associated with change in working memory score [39]. 
Retrospectively, a VBM study of WM in cancer survivors showed distributed 
decreases in subcortical WM density compared to healthy controls [35]. Patients 
with memory complaints an average of two years post-chemotherapy showed 
decreased DTI WM integrity in the genu but not splenium of the corpus callosum 
compared to healthy controls in a region-of-interest analysis, and decreased 
genu integrity was associated with slower processing speed [40]. Another 
retrospective VBM study showed lower WM in distributed regions four months 
post-chemotherapy compared to non-chemotherapy-treated BC patients; 
precuneus WM was associated with attention scores. In the same study in a 
partially overlapping cohort VBM found no WM differences in chemotherapy-
treated patients 2.6 years post-chemotherapy. Nine years post-chemotherapy 
DTI has revealed lower WM integrity in widely distributed tracts compared to non-
chemotherapy-treated BC patients [37]. Finally, a study of BC patients 3-5 
months post-chemotherapy showed lower WM integrity in frontal and temporal 
WM tracts compared to non-chemotherapy-treated BC patients and healthy 
controls. These alterations were correlated with attention, processing speed, and 
self-reported cognitive function [41]. In summary, chemotherapy appears to 
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negatively affect WM density and tract integrity, an effect that persists for years 
and perhaps decades following treatment. WM alterations are associated with 
poorer subjective and objective cognitive function. There is no evidence for pre-
treatment alterations in WM in BC patients. WM alteration is consistent with the 
processing speed alterations often observed post-chemotherapy.  
 
PET studies have shown physiological changes related to cancer and treatment. 
In an FDG-PET study, cancer patients in 4 categories (pre-chemotherapy, post-
chemotherapy, recurrent, and terminal) showed resting hypometabolism in 
distributed brain regions compared to healthy controls. Interestingly, the pre-
chemotherapy group showed the greatest degree of hypometabolism [42]. 
Another FDG-PET study did not reveal any differences 5-10 years post-
chemotherapy compared with non-chemotherapy-treated BC patients, although 
resting metabolism in the left inferior frontal cortex of BC patients was positively 
correlated with performance in visuospatial memory [43]. In the same study, 15O-
H2O imaging showed relatively greater blood flow during a verbal memory task in 
chemotherapy-treated patients, with peak blood flow change in the inferior frontal 
gyrus.  
 
Both cancer- and treatment-related effects have been detected with fMRI. A 
pretreatment study showed greater inferior frontal and parietal and lower anterior 
cingulate activity during a working memory task in BC patients compared to 
healthy controls. Task performance was lower in the patients [44]. In the first 
prospective longitudinal fMRI study in BC, our laboratory showed pre-treatment 
frontal hyperactivation and parietal hypoactivation during a working memory task 
in BC patients compared to healthy controls [45]. BC patients treated both with 
and without chemotherapy showed relative decreases in frontal regions from pre- 
to one month post-chemotherapy (or an equivalent interval in non-chemotherapy-
treated patients). One year later, both groups showed increased frontal activity, 
partially returning to their baseline hyperactive state. In the chemotherapy group, 
the left frontal region of maximal change overlapped with a region demonstrating 
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decreased GM density in the same cohort [33], suggesting a structure-function 
relationship, and performance on the in-scanner working memory task was 
decreased one month post-chemotherapy, suggesting that frontal hyperactivation 
was compensatory.  
 
Retrospective fMRI studies have also proved informative. An initial report of 
monozygotic twins discordant for BC and chemotherapy showed greater 
activation throughout task-activated regions in the affected twin 22 months post-
chemotherapy. Task performance was similar in both twins, suggesting 
compensatory hyperactivation in the BC twin [46]. A study of BC survivors nine 
years post-chemotherapy showed decreased frontal and parietal activation 
during an executive function task compared to non-chemotherapy-treated BC 
survivors, and frontal activation in the chemotherapy group was significantly 
positively correlated with in-scanner task performance [47]. In the same study, 
fMRI during an episodic memory task showed lower parahippocampal gyrus and 
parietal activation in the chemotherapy group. Subsequent performance on a 
recognition task of items encoded during the in-scanner task was correlated with 
parahippocampal gyrus activation. A subsequent study on the same cohort 
showed striking anatomic overlap of both GM and WM chemotherapy-associated 
alterations with chemotherapy-affected regions on fMRI [37]. In chemotherapy-
treated BC patients a mean of three years post-treatment, lower frontal activation 
during a memory encoding task was observed compared to healthy controls. 
However, during memory retrieval, BC patients showed diffusely greater 
activation. Performance on the in-scanner memory task was similar between 
groups [48]. Finally, five years post-treatment, BC patients treated with or without 
chemotherapy showed lower activation in several prefrontal regions during an 
executive function task compared to healthy controls. In another prefrontal region 
activation was lower in chemotherapy-treated BC patients compared to non-
chemotherapy-treated patients and healthy controls, suggesting that a greater 
degree of hypoactivation relative to healthy controls occurred in chemotherapy-
treated BC patients compared to non-chemotherapy-treated patients. Behavioral 
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measures were correlated with imaging results in this study: in chemotherapy-
treated patients, lower prefrontal activation was associated with greater 
subjective executive function complaints, and in healthy controls greater 
activation was associated with lower executive function complaints and faster 
executive function task performance [49].  
 
Taken together, fMRI studies show a pattern of pre-treatment and early post-
treatment compensatory frontal activation. Frontal changes are consistent with 
working memory and executive function changes observed in BC. Many years 
post-chemotherapy, frontal hypoactivation is present compared to either non-
chemotherapy-treated or cancer-free controls, which might reflect late sequelae 
of chemotherapy. In many of these studies, neurocognitive performance was 
correlated with alterations in brain function. Several studies show evidence of 
anatomically overlapping structural and functional effects. 
 
In summary, neuroimaging studies of BC patients show post-chemotherapy 
structural changes and both pre- and post-chemotherapy functional changes. 
The frontal lobes appear to be the most broadly affected. Many alterations seen 
on imaging have shown neurocognitive correlates, suggesting functional 
relevance. These studies occurred at a range of post-treatment intervals, from 
months to decades. The trajectory of such changes over time, i.e., the effect of 
post-chemotherapy interval, has not been formally studied. Also unclear is the 
neural impact of systemic estrogen changes in breast cancer patients resulting 
from chemotherapy-induced amenorrhea (CIA) or hormonal treatments. As it is 
critical to brain function, estrogen likely plays an important role in cancer- and 
treatment-related cognitive dysfunction in BC. 
 
Estrogen and the brain 
The cognitive and neural effects of estrogen across the lifespan are an active 
area of research, as estrogen is critically involved in memory processing. Steroid 
hormone levels decrease with age in both men and women [50, 51]. The 
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menopausal transition is characterized by a loss of ovarian-produced estrogen in 
females around the age of 50, and cognition during and after this period has 
been a particular focus of study. Up to 60% of women report cognitive problems 
associated with menopause [52], and longitudinal studies have shown 
dysfunction peaking during the perimenopausal period [53, 54]. Age-related 
decreases in circulating estrogen, particularly in association with the menopausal 
transition, have adverse cognitive effects [55, 56]. Estrogen loss reduces 
neuroplasticity and longer duration of estrogen deprivation (i.e., more time after 
menopause) is associated with worse outcomes [57]. The “healthy cell bias 
theory of estrogen action” posits that estrogen replacement would be effective 
only before estrogen loss has injured the cell beyond repair via dysregulation of 
mitochondrial and bioenergetic processes [58]. This is consistent with studies 
showing that the cognitive benefits of hormonal replacement therapy (HRT) 
appear to depend on timing and formulation of treatment [59, 60]. Also, abrupt 
estrogen loss in pre-menopausal women, either by oophorectomy or treatment 
with gonadotropin releasing hormone (GnRH) agonists, has been linked to 
cognitive dysfunction [61]. 
 
The pleiotropic actions of estrogen in the brain suggest a host of potential 
biological mechanisms for estrogen depletion-related cognitive dysfunction. 
While the majority of circulating estrogen in premenopausal females is produced 
by the ovaries, neural estrogen is produced by the enzyme aromatase in 
neurons, astrocytes, and cerebrovascular endothelial cells in both genders [62]. 
Both estrogen receptor-α (ER-α) and ER-β are distributed throughout the brain. 
Estrogen is neurotrophic and neuroprotective in vitro and in vivo [62]. Estrogen is 
anti-inflammatory in the brain via reduction of microglial activation, and is 
neuroprotective in ischemia and oxidative stress [63]. Neuroplastic processes, 
including synaptogenesis and neurogenesis, are regulated by estrogen [57]. The 
genes of several neural growth factors, including BDNF and VEGF, have 
estrogen response elements, thus altering their expression in response to an 
estrogen stimulus [64]. Estrogen also interacts with many neurotransmitter 
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systems, including acetylcholine, serotonin, glutamate, and dopamine [65], and 
regulates vasodilation of cerebral blood vessels [66]. Estrogen downregulates 
several molecular pathways associated with Alzheimer’s disease (AD) pathology. 
Estrogen is associated with: decreased amyloidogenic processing of amyloid 
precursor protein (APP) [67, 68], which may lead to decreased amyloid plaque 
deposition; inhibition of the enzyme glycogen synthase kinase-3β, which is 
critical in creating the hyperphosphorylated tau that makes up neurofibrillary 
tangles; and increased expression of choline acetyltransferase (ChAT), an 
enzyme known to be deficient in AD, leading to impaired cholinergic 
neurotransmission [69]. The involvement of estrogen in this variety of neural 
processes underlies its functional importance in higher-level processes such as 
cognition. 
 
In light of the estrogen pathway’s involvement with many crucial neural 
processes, it is not surprising that genetic variation leading to alterations in 
estrogen synthesis, response, or degradation has been implicated in cognition 
and cognitive disorders. ESR1, the gene coding for estrogen receptor (ER)-α, 
has been particularly well studied. Many studies have shown association of 
ESR1 polymorphisms with decreased cognitive function or risk of dementia (for 
systematic review, see [70]). Polymorphisms in ESR1 have also been shown to 
interact with the apolipoprotein E (APOE) ε4 allele, the genetic marker conferring 
greatest AD risk [71-73]. Risk of dementia has also been associated with 
polymorphisms in ESR2 [74, 75], which codes for ER-β, and CYP19A1 [76-78] 
which codes for aromatase, the enzyme that synthesizes estrogen from 
testosterone (see [70, 79] for review). 
 
Neuroimaging has provided insight about brain changes that underlie the 
relationship between estrogen and cognition [80] via comparison of high-
estrogen and low-estrogen states. Structural MRI studies have found diminished 
gray matter in postmenopausal women not using HRT vs. those currently using 
HRT [81-85], although some have found no such relationship [86]. fMRI studies 
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have demonstrated a pattern of lower task-related activation in postmenopausal 
women not receiving HRT relative to those who are [87-91], in younger women 
after gonadotropin releasing hormone agonist (GnRHa)-induced ablation of 
ovarian estrogen production [92-94], and during the low as compared to high 
estrogen phase of the menstrual cycle [95, 96]. These functional changes occur 
most commonly in prefrontal, temporoparietal, precentral, and paracentral 
regions. Several studies using single photon emission computerized tomography 
(SPECT) or (15O)-H2O PET have shown lower cerebral blood flow in 
postmenopausal women not receiving HRT as compared to postmenopausal 
women receiving HRT [97-101] and premenopausal women [100]. Overall, 
decreased levels of estrogen have been associated with lower gray matter 
density, task-related brain activation, and cerebral blood flow. 
Hormonal changes in breast cancer 
Breast cancer treatment can influence systemic estrogen in several ways. First, 
80% of pre- or peri-menopausal breast cancer (BC) patients undergoing current 
widely-used chemotherapy regimens (cyclophosphamide and doxorubicin, with 
or without a taxane) experience chemotherapy-induced amenorrhea (CIA) in the 
months immediately following chemotherapy [102-105]. CIA results from 
disruption of normal ovarian follicular maturation, leading to markedly decreased 
systemic estrogen levels [106], and is associated with increased survival due to 
the loss of estrogen’s trophic effects on estrogen receptor-positive tumors [102, 
107]. CIA negatively impacts quality of life, as patients undergoing CIA appear to 
experience more severe symptoms than women undergoing natural menopause 
[108]. Prospective studies have shown decline or failure to improve with practice 
in multiple cognitive domains in patients undergoing CIA compared to patients 
undergoing chemotherapy but not amenorrhea [109, 110], although other studies 
found no such effect [111-113]. Timing of measurements appears to play a role. 
As time passes after chemotherapy, 20-60% of women pre- or peri-menopausal 
before treatment experience continued amenorrhea [105, 114, 115]. Many 
factors influence resumption of menses, including tamoxifen therapy [115]. 
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For the approximately 75% of breast cancer patients who have estrogen 
receptor-positive tumors, a several-year course of an aromatase inhibitor (AI) or 
selective estrogen response modulator (SERM) such as tamoxifen is 
recommended to prevent recurrence. AIs block the production of estrogen 
throughout the body and thus decrease circulating estrogen levels, while SERMs 
act as estrogen agonists or antagonists, depending on the tissue, and do not 
affect circulating estrogen levels [116].  
 
In BC patients cognitive dysfunction has been associated with both AIs and 
SERMs [85, 117-121], although other studies have failed to demonstrate such a 
relationship [111, 122-126]. AIs and SERMs have different neural effects as 
observed in animal models. Decreased aromatase activity, either through AI 
administration or knock-out of the aromatase gene, has been associated with 
decreased neurogenesis, increased damage from excitotoxicity, and increased 
ischemic damage [65]. SERMs, on the other hand, appear to have a variety of 
neurotrophic effects, although estrogen agonistic or antagonistic activity varies 
among brain regions and between SERMs. Some SERMs have antioxidant and 
anti-inflammatory properties in the brain [127].  
 
A few cross-sectional, retrospective imaging studies have explored the neural 
effects of tamoxifen. Decreased resting metabolism in the basal ganglia has 
been demonstrated in breast cancer patients with a history of tamoxifen and 
chemotherapy as compared to patients receiving chemotherapy but not 
tamoxifen, patients receiving neither chemotherapy nor tamoxifen, and healthy 
controls [43]. Breast cancer survivors receiving tamoxifen also showed resting 
hypometabolism in frontal and postcentral regions compared to women without 
cancer regardless of HRT status [85]. An MR spectroscopy study found lower 
overall myoinositol levels in women receiving tamoxifen or HRT as compared to 
postmenopausal women receiving neither. Since increased myoinositol is 
associated with injury-related increases in glial activity, this study concluded that 
tamoxifen and HRT have neuroprotective effects [128]. Overall, the little existing 
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literature suggests resting hypometabolism in BC patients using tamoxifen. 
However, no neuroimaging studies of AI treatment or CIA exist, nor are there any 
prospective neuroimaging studies of treatment-related hormonal changes in BC. 
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Current Studies and Significance 
The precise time course and biological mechanisms by which BC and/or 
alterations in estrogen status lead to cognitive and brain changes remain unclear. 
The following three chapters use advanced neuroimaging, cognitive testing, 
genetics, and biomarker analysis to investigate the ways in which post-
chemotherapy interval, chemotherapy-induced amenorrhea, and genetic 
variation in the estrogen pathway affect the brain.  
 
Despite a number of retrospective studies and several emerging prospective 
studies of the effects of chemotherapy on brain structure and function, the time 
course of neural changes that occur during survivorship is unclear. Chapter 1 of 
this document examines the association of post-chemotherapy interval (PCI) with 
gray matter density and working memory-related brain activation in BC survivors 
with PCIs ranging from 3-10 years (mean 6.4). The relationships among PCI, 
neuroimaging, cognitive changes and biological markers could help elucidate 
important mechanisms. We hypothesized that in BCS compared to healthy 
controls, there would be increased cognitive dysfunction, changes on 
neuroimaging, and oxidative and direct DNA damage and that these would be 
associated with shorter PCI. Notably, this study is the first to address the 
relationship between peripherally measured oxidative stress and brain structure 
in BC, possibly providing a mechanistic clue to cognitive dysfunction in BC 
patients.  
 
Chemotherapy-induced amenorrhea (CIA) accompanied by loss of systemic 
estrogen often occurs in pre- and peri-menopausal BC patients, and while 
cancer/chemotherapy and abrupt estrogen loss have separately been shown to 
affect cognition and brain function, studies of the cognitive effects of CIA are 
equivocal, and its effects on brain function are unknown. Chapter 2 prospectively 
investigates the effects of CIA by comparing patients undergoing CIA to BC 
patients already postmenopausal at chemotherapy initiation using fMRI prior to 
and one month after chemotherapy completion. We hypothesized that the CIA 
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profile of activation and deactivation during a working memory task would be 
distinct from that of post-menopausal patients undergoing chemotherapy or 
healthy controls. We assessed the relationship between changes in brain activity 
and cognition in order to determine the functional significance of observed neural 
effects. 
 
Chapter 3 addresses the role of estrogen in the brain more generally. Cognitive 
and neurodegenerative phenotypes have been associated with genetic variation 
in estrogen pathway genes, particularly ESR1, the gene that codes for estrogen 
receptor-α. We used structural imaging to determine the effect of ESR1 
polymorphisms on brain structure in healthy older male and female adults from 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI). We hypothesized that 
ESR1 genotype could explain variance in hippocampal and amygdalar volumes 
and whole-brain gray matter density, and that these effects would vary by 
gender. In light of epidemiological and molecular evidence, we also hypothesized 
that APOE-ε4 genotype would interact with ESR1 in influencing brain 
phenotypes. 
 
The findings from the above studies may have future implications for informed 
treatment decisions by BC patients and their physicians. By studying the impact 
of estrogen loss during CIA, we hope to add to the literature on brain changes in 
BC that has previously focused almost completely on chemotherapy effects. Our 
findings will also contribute to a more general understanding of neural estrogen’s 
role in cognition and cognitive dysfunction. We believe that these studies will be 
a step toward future development of neuroprotective or rehabilitative 
interventions, either pharmacological or behavioral, for detrimental BC- and 
estrogen-related neural effects.  
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Chapter 1: Alterations in brain structure and function in breast cancer 
survivors: effect of post-chemotherapy interval and relation to oxidative 
DNA damage 
Neuroimaging studies have begun to uncover the neural substrates of cancer 
and treatment-related cognitive dysfunction, but the time course of these 
changes in the years following chemotherapy is unclear. In this chapter, we 
analyzed multimodality 3T MRI scans to examine the structural and functional 
effects of chemotherapy and post-chemotherapy interval (PCI) in a cohort of 
breast cancer survivors (BCS; n=24; PCI mean 6, range 3-10 y) relative to age- 
and education-matched healthy controls (HC; n=23). Assessments included 
voxel-based morphometry (VBM) for gray matter density (GMD) and functional 
MRI (fMRI) for activation profile during a 3-back working memory task. The 
relationships between brain regions associated with PCI and neuropsychological 
performance, self-reported cognition, and peripheral oxidative and direct DNA 
damage were assessed in secondary analyses. Cognitive complaints and 
oxidative DNA damage were increased, and memory performance decreased, in 
BCS compared to HC. Imaging results indicated lower GMD and fMRI activation 
in several regions in the BCS group. PCI was associated with GMD and 
activation in the right anterior frontal region (Brodmann Areas 9 and 10) 
independent of participant age. GMD in this region was also correlated with 
global neuropsychological function. In regions where BCS showed decreased 
GMD this was inversely related to oxidative DNA damage and learning and 
memory neuropsychological domain scores. This is the first study to show 
structural and functional effects of PCI and to relate DNA damage to brain 
alterations in BCS. The relationship between neuroimaging and cognitive 
function indicates the potential clinical relevance of these findings. The 
relationship with peripheral oxidative DNA damage suggests a potential 
mechanism of chemotherapy-related neural changes warranting further 
investigation.  
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Introduction 
Increasing evidence shows cognitive changes related to breast cancer and its 
treatments, as demonstrated by lower than expected performance on 
neuropsychological tests. Changes occur particularly in executive function 
(including working memory) and processing speed domains (for meta-analysis 
and review see [3-6]). Self-report measures show increased perceived cognitive 
difficulties in cancer patients (see [9] for review).  
 
Imaging studies have recently begun to reveal the neural substrates of such 
changes. Retrospective MRI studies have shown post-chemotherapy structural 
alterations in both gray [36-38] and white matter [40, 41] in cohorts of breast 
cancer survivors (BCS) whose average post-chemotherapy intervals (PCIs) 
ranged from four months to 21 years. Retrospective functional MRI (fMRI) 
studies have shown hypoactivation during cognitive tasks, at an average of 4.7 
years [49] or 10 years [47] post-chemotherapy, compared to BCS who never 
received chemotherapy. De Ruiter et al. demonstrated links between structural 
and functional results in in a single cohort approximately 10 years post-
chemotherapy (compared to non-chemotherapy-treated BCS), with gray and 
white matter changes overlapping with regions of fMRI hypoactivation [37]. 
Recently, prospective structural, functional and diffusion tensor MRI studies [33, 
39, 45] have shown changes after treatment, particularly in the frontal cortex. The 
recent prospective data is particularly important given reports of cognitive [7] and 
functional [44, 45, 129] changes prior to treatment.  
 
Many biological mechanisms for cancer- and treatment-associated cognitive 
dysfunction and brain changes have been proposed; prominent among them are 
oxidative stress, DNA damage, and compromised DNA repair, all of which may 
be shared risk factors for development of cancer and sensitivity to cancer- and 
treatment-related neurological side effects [10]. Many chemotherapeutic agents 
are known to produce DNA damage and/or free radicals, which cause oxidative 
damage. Increased oxidative and endogenous DNA damage in white blood cells 
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have been demonstrated in women with breast cancer pre-treatment, and these 
changes are exacerbated after chemotherapy [130].  
 
Despite recent progress, the time course of changes during survivorship is poorly 
understood. The current study examines the association of PCI with gray matter 
density (GMD) and working memory-related functional MRI (fMRI) brain 
activation in BCS. The relationships among PCI, neuroimaging, cognitive 
changes and biological markers could help elucidate important mechanisms of 
chemotherapy-related neural changes. We hypothesized that in BCS compared 
to healthy controls there would be increased cognitive dysfunction, changes on 
neuroimaging, and oxidative and direct DNA damage, and that these would be 
associated with shorter PCI.  
 
Methods 
Participants 
BCS with a history of non-metastatic disease and chemotherapy treatment and 
age- and education-matched healthy controls (HC) were recruited as part of a 
larger study of the cognitive sequelae of cancer and its treatments [131, 132], so 
the sample had prior assessment with a subset of neuropsychological measures 
2-3 years earlier. In the present study, 27 BCS and 25 HC underwent structural 
and functional MRI exams as well as a battery of neuropsychological tests and 
self-report measures. Blood was obtained for biomarker analysis, including 
comet assays to assess DNA damage (see below). Four participants were 
excluded from all analyses: one HC for current use of antipsychotic medication, 
two BCS for history of stroke, and one BCS for extremely poor performance (>4 
SD below the control mean) on neuropsychological tests that was thought to be 
due to a comorbid condition.  
 
Image Acquisition, Processing, and Analysis 
All images were acquired on the same Siemens MAGNETOM Tim Trio 3T scanner 
using a 12-channel head coil as previously described [34, 45]. Structural scans 
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were a sagittal T1-weighted MP-RAGE (magnetization prepared rapid gradient 
echo) sequence with the parameters: 160 contiguous 1.2mm slices, TR: 2300ms, 
TE: 2.91ms, TI: 900ms, flip angle: 9, NEX: 1, BW/Pixel: 240, FOV: 256mm, matrix 
256x256, in-plane resolution: 1.0×1.0 mm. Blood oxygenation level-dependent 
(BOLD) fMRI images were acquired axially with a T2*-weighted single shot echo-
planar imaging (EPI) pulse sequence with the parameters: TR: 2250ms, TE: 29ms, 
flip angle: 79, FOV: 220mm, matrix: 88×88, slice thickness: 3.5mm, NEX: 1, 
yielding 39 contiguous axial slices and a voxel dimension of 2.5x2.5x3.5mm.  
 
As in our prior fMRI studies of breast cancer patients [45, 46] a block design 
verbal “N-back” task was used. During scanning, participants saw a series of 
consonant letters (except L, W, and Y), presented one every three seconds. Task 
conditions were 0-, 1-, 2-, and 3-back. Each condition was presented in 27-
second epochs preceded by three seconds of instruction (e.g., “the match is one 
back”). For each letter participants responded via button press to indicate 
whether the current letter was a match (i.e., was the same as the designated 
target or the letter presented 1, 2, or 3 back in the sequence, depending on the 
condition) or a non-match. The four experimental conditions were each 
presented three times in pseudorandom order for a total of 12 task blocks (total 
duration = 6:54). Participants practiced a version of the task prior to scanning to 
ensure comprehension of the task. Presentation software (Neurobehavioral 
Systems, Inc., Albany, CA) was used to program the task and record response 
accuracy and reaction times.  
 
Image processing for VBM used in-house MATLAB (Version 7.9 (R2009b), 
Mathworks, Inc., Natick, MA) scripts to implement optimized VBM methods [133-
135] using Statistical Parametric Mapping software (SPM; Version 8, Wellcome 
Department of Imaging Neuroscience, London, UK), similar to our prior studies 
[33, 45, 136-138]. Briefly, after reconstruction, scans were registered to the 
Montreal Neurological Institute T1-weighted template and segmented into gray 
matter, white matter, and cerebrospinal fluid compartments using the MNI T1-
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weighted template and corresponding tissue probability maps. Gray matter maps 
were then spatially normalized to MNI space, resampled to 1mm isotropic voxels, 
and smoothed using an isotropic Gaussian spatial filter (FHWM = 10mm). The 
smoothed, normalized gray matter maps were used for second-level multi-
subject voxelwise analyses. The SPM8 prior probability gray matter template was 
used to restrict statistical comparisons to the gray matter compartment. 
 
fMRI image processing also utilized SPM8. Spatial realignment using a six 
parameter model was performed on raw scan data to remove minor motion-
related signal change. Realignment parameters were entered as covariates at 
the subject level, and all volumes were normalized into standardized atlas space, 
resampled to 2 mm3 isotropic voxels, and smoothed to a FWHM of 8mm. 
Contrast images comparing pairs of working memory load conditions (e.g., 3-
back > 0-back) were created for each participant. These contrast images were 
then used in second-level multi-subject voxelwise analyses. Mixed model 
analyses accounted for both random effects (scan) and fixed effects (task 
condition). 
 
Voxelwise random effects analyses for both VBM and fMRI were conducted 
using linear regression (for PCI) or t-tests (between-group analysis) as 
implemented in SPM8 to construct maps of voxels in which local GMD or 
activation differed as a function of PCI or between BCS and HC groups. Age was 
included as a covariate in all group analyses. Statistical significance was set at 
an uncorrected voxel-level pcrit of 0.001 and a minimum cluster size (k) of 10 
voxels. In fMRI comparisons, a mask of the main effect of the 3-back > 0-back 
comparison (pcrit = 0.05) in all participants was applied in order to search in only 
regions of task-related activation. 
 
In order to correlate imaging data with behavioral and comet assay data, 
MarsBaR v0.42 (http://marsbar.sourceforge.net/) was used to extract mean GMD 
or activation values from each statistically significant cluster. To reduce 
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dimensionality of imaging data from each analysis, these mean cluster values 
were averaged to create an overall mean value of significant clusters for each 
analysis.  
 
Neurocognitive Testing and Self-Report Measures 
Raw neurocognitive test scores were normalized using the mean and standard 
deviation of the HC group scores. Domain scores were created for each 
participant by averaging the z-scores of the included tests. Domain scores were 
then adjusted for age. The learning domain consisted of the Rey Auditory-Verbal 
Learning Test (AVLT) total learning score [139, 140], story recall (immediate) 
[141], and the sum of recalled items for initial learning trials on the Brown 
Learning Test (BLT) [142]. The memory domain comprised Rey AVLT delayed 
recall, story recall (10 minute delay) [141], and BLT long delay score. The 
attention domain included Wechsler Adult Intelligence Scale (WAIS-III) Digit 
Span forward total score [143] and the Rao Paced Auditory Serial Addition Test 
(PASAT) 2 and 3 minute trial total scores [144]. The language domain included 
the Wide Range Achievement Test (WRAT-4) Word Reading test [145] and the 
Wechsler Abbreviated Scale of Intelligence (WASI) Vocabulary test [146]. The 
visuospatial domain was the WASI Block Design raw score. The executive 
domain consisted of the Digit Span backward total score, the Controlled Oral 
Word Association (COWA) Test total score [139, 140], Delis-Kaplan Executive 
Function System (D-KEFS) Color-Word Interference Test inhibition and 
inhibition/switching trials times [147], D-KEFS Sorting Test number of correct 
sorts, and D-KEFS Trail Making Test number-letter switching trial time. The 
psychomotor domain consisted of D-KEFS Color-Word Interference Test color 
naming trial time, D-KEFS Trail Making Test number sequencing trial time, 
Symbol Digit Modalities Test oral total score [148], and Grooved Pegboard total 
time [149]. 
 
Self-reported cognition was assessed using the Multiple Ability Self-Report 
Questionnaire (MASQ) [150] and the Functional Assessment of Cancer Therapy-
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Cognitive Function (FACT-COG) [151]. It should be noted that, unlike other self-
report data presented, higher scores on the FACT-COG are indicative of 
decreased cognitive complaints. The Center for Epidemiologic Studies-
Depression Scale (CES-D) [152] and the State-Trait Anxiety Inventory-State 
Scale (STAI-S) [153] were used to assess depression and anxiety symptoms.  
 
Comet Assay 
The comet assay for assessment of direct and oxidative DNA damage was 
performed as described previously with modifications [154-156]. For white blood 
cells (WBC), immediately after the blood samples were taken, 2 µl whole blood 
was mixed with 70 µl 1% low-melting agarose and applied onto Trevigen 
CometSlides (Trevigen, Gaithersburg, MD). After the gel solidified, cells were 
lysed (100mM Na2EDTA, pH 10, 2.5M NaCl, 10mM Trizma base, 1% sodium 
lauryl sarcosinate, 1% Triton-X 100, 10% DMSO, and 1mM deferoxamine; 1 h), 
placed in alkali buffer (0.3M NaOH and 1mM Na2EDTA, pH > 13; for 40 min at 
4°C), and then electrophoresed in alkali buffer (25 V, 300 mA, 30 min). Following 
electrophoresis, slides were neutralized (0.4M Tris, pH 7.5, at 4°C for 5 min), 
rinsed in distilled water (at 4°C for 15 min), and allowed to dry at room 
temperature in the dark. After slides were stained with ethidium bromide (25 µg; 
20 µg/ml) and covered with a cover slip, a total of 100 nuclei/treatment selected 
at random per slide were evaluated on a Nikon fluorescence microscope using 
Komet 4.0 imaging Software (Kinetic Imaging Ltd., Liverpool, UK). DNA damage 
was expressed as comet (Olive) tail moment ([tail mean - head mean] x 
tail%DNA/100) [154, 157]. For the assessment of oxidative DNA damage, a 
modified alkaline comet assay was performed that included enzymatic digestion 
with formamidopyrimidine DNA glycosylase (fpg) prior to electrophoresis. Briefly, 
after the lysis of cells, slides were washed (40mM 4-[2- hydroxyethyl]piperazine-
1-ethanesulfonic acid, 100mM KCl, 0.5mM Na2EDTA, and 0.2% bovine serum 
albumin; pH 8.0, 5 min, 3x) and then incubated with fpg solution or buffer (100 µl 
for 40 min at 37°C). Slides then underwent alkaline unwinding and the remainder 
of the procedure as described above.  
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Statistical Analyses 
Linear regression within BCS only was used to assess the effect of PCI on self-
reported cognition, neuropsychological test scores, and DNA damage. T-tests 
were used to assess significance of between-group effects with these same 
variables. To examine the possible pattern of relationships between imaging 
results and other key variables, we tested the association between mean GMD 
and activation values with the above measures separately in each group using 
regression analyses. For these secondary analyses, a liberal significance 
threshold of p ≤0.05 was employed due to the relatively small sample size and 
likely non-independence among cognitive variables. 
 
Results 
Demographic information, self-report, comet assay, neuropsychological domain, 
and cancer- and treatment-related information are shown in Table 1-1. Groups 
did not differ in age, education, handedness, APOE status, estimated IQ, STAI-S, 
or CES-D scores. Patients were an average of 6.4 years post-chemotherapy 
(range: 3.2-10.2). PCI was not significantly correlated with age (r = -0.086, p = 
0.688).  
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Table 1-1 Demographic, self-reported cognition, DNA damage, 
neuropsychological domain, and breast cancer treatment information. Values 
shown are mean ± SD; asterisks indicate between group p ≤ 0.05. 
 
 Healthy 
Control 
Breast 
Cancer 
Survivors 
N 23 24 
Age (years)  61.2±9.9 57.8±9.6 
Education (years) 16.0±2.3 15.7±2.1 
Handedness (R:L) 19:4 22:2 
APOE e4 allele 
positive 
16 16 
Full Scale IQ 
Estimate (Barona 
Index [158]) 
113.4±3.9 113.3±4.3 
CES-D raw score 8.7±6.9 7.5±5.8 
STAI-S raw score 31.9±9.1 30.2±7.9 
3-back score 
(corrected for 
guessing) 
54.1±21.9 53.7±21.2 
3-back reaction time 
(seconds) 
0.772±0.186 0.825±0.200 
FACT-COG total raw 
score* 
135.3±13.0 116.2±28.8 
MASQ total raw 
score* 
79.9±17.7 97.1±20.3 
Direct DNA damage 
(alkaline comet 
assay tail moment) 
1.0±0.3 0.8±0.3 
Oxidative DNA 
damage (fpg comet 
assay tail moment)* 
1.0±0.6 1.5±1.2 
Age-adjusted 
neuropsychological 
domain z-scores: 
  
Learning 0.2±0.7 -0.2±0.7 
Memory* 0.03±0.5 -0.3±0.6 
Attention 0.1±0.7 0.4±0.6 
Language -0.03±0.9 0.3±0.8 
Visuospatial 0.1±0.9 -0.5±1.0 
Executive 0.04±0.6 -0.04±0.7 
Psychomotor 0.04±0.4 -0.1±0.4 
Average 0.1±0.4 -0.1±0.5 
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Patient Information   
Age at diagnosis  51.2±10.1 
Received radiation  19 
Received tamoxifen  13 
Received aromatase 
inhibitor 
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Average post-
chemotherapy to 
MRI interval (years) 
 6.4±2.1 
(range 3.2-
10.2) 
Stage I number of 
patients (percent) 
 7 (29) 
Stage IIa  8 (33) 
Stage IIb  6 (25) 
Stage IIIa  2 (8) 
Stage IIIb  1 (4) 
Chemotherapy 
regimens: 
  
Doxorubicin, 
cyclophosphamide 
(AC) 
 
7 
Doxorubicin, 
cyclophosphamide, 
taxane (AC-T) 
 
5 
Doxorubicin, 
cyclophosphamide, 
5-fluorouracil (CAF) 
 
2 
Doxorubicin, taxane 
(A-T) 
 
3 
Cyclophosphamide, 
methotrexate, 5-
fluorouracil (CMF) 
 
2 
CMF and CAF  1 
Taxane only  1 
AC-T and 
capecitabine 
 
2 
Taxane and 
capecitabine 
 
1 
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Post-chemotherapy interval 
Imaging 
In voxelwise regressions with PCI (BCS group only), structural and functional 
effects converged anatomically in the right anterior frontal lobe (Figure 1-1): GMD 
was positively correlated with PCI in the right superior and middle frontal gyri 
(Brodmann Areas (BA) 9, 10) and activation was negatively correlated with PCI 
in the right middle frontal gyrus (BA 10). Greater GMD was associated with 
longer PCI in 10 clusters within the bilateral frontal and parietal lobes and basal 
ganglia, as well as the right temporal lobe (Table 1-2). No regions were evident in 
which lower GMD was associated with longer PCI or in which activation was 
positively correlated with PCI.  
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Figure 1-1 Functional and structural overlap in the right anterior middle frontal 
gyrus, in which gray matter density (red) was positively correlated with post-
chemotherapy interval and working memory-related activation (blue) was 
negatively correlated with post-chemotherapy interval (voxelwise p uncorrected = 
0.001, cluster size=10 for both modalities). 
  
 
R 
R 
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Table 1-2 Statistically significant clusters from imaging analyses (voxel-level p 
uncorrected = 0.001, cluster size = 10 voxels for all analyses).  
Peak MNI 
coordinates 
(x y z) 
Cluster 
extent 
(k) 
Cluster-
level 
pcorrected 
(FWE) 
Cluster-
level 
puncorrected 
Z 
Region 
description of 
local maxima 
within cluster 
 
Brodmann 
Area (BA) 
VBM: Positive Correlation with time since chemotherapy 
9 9 42 79 0.996 0.465 4.15 
Right cingulate 
gyrus 
32 
64 8 8 160 0.970 0.294 4.10 
Right precentral 
gyrus 
44 
37 37 33 608 0.453 0.051 4.09 
Right superior and 
middle frontal gyri 
9, 10 
20 21 5 73 0.997 0.484 3.63 Right caudate N/A 
-8 16 47 48 0.999 0.577 3.50 
Left cingulate 
gyrus 
32 
-21 11 -23 105 0.991 0.396 3.44 
Left inferior frontal 
gyrus 
47 
-21 20 2 11 >0.999 0.814 3.44 Left putamen N/A 
15 -80 33 26 >0.999 0.694 3.42 Right precuneus 7 
-9 83 14 37 0.999 0.630 3.38 Left cuneus 18 
64 -20 -2 40 0.998 0.615 3.35 
Right superior 
temporal gyrus 
21 
3-back > 0-back: Negative correlation with time since chemotherapy 
40 52 16 16 0.922 0.095 3.84 
Right middle 
frontal gyrus 
10 
VBM: Healthy Control > Breast Cancer Survivor 
-43 -67 8 143 0.971 0.411 3.67 
Left middle 
temporal gyrus 
37 
16 -26 -4 188 0.948 0.344 3.60 Right midbrain  N/A 
-14 -23 6 408 0.762 0.167 3.58 Left thalamus N/A 
2 -23 -17 184 0.950 0.349 3.53 Right midbrain N/A 
38 -66 -39 461 0.709 0.143 3.48 Right cerebellum N/A 
49 -21 23 59 0.995 0.611 3.37 Right insula 13 
3-back > 0-back: Healthy Control > Breast Cancer Survivor 
10 -68 42 23 0.808 0.080 3.56 Right precuneus 7 
-28 -66 22 15 0.954 0.150 3.47 
Left middle 
temporal gyrus 
39 
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3-back task performance and reaction times, cognitive testing, self-reports, and 
comet assay 
 
PCI was not significantly correlated with 3-back task performance or reaction 
time, any neuropsychological domain or self-report measure, or DNA damage. 
 
Relationship of imaging to other measures 
In secondary analyses, the mean GMD value of the right frontal cluster depicted 
in Figure 1-1 (red) was positively correlated with the overall neuropsychological 
performance (mean domain score, r = 0.434, p = 0.044) (Figure 1-2). The mean 
activation of the 3-back cluster depicted in Figure 1-1 (blue) was not associated 
with any other measures at p ≤ 0.05. The average of all GMD clusters derived 
from a positive correlation with PCI was not associated with any other measures 
at p ≤ 0.05.  
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Figure 1-2 In breast cancer survivors (BCS), the average of neuropsychological 
domain z-scores vs. mean gray matter density in right middle and superior frontal 
gyri (Brodmann Areas 9, 10). 
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Between-group analyses 
Imaging 
Imaging analyses revealed differences between the BCS and HC groups. BCS 
showed decreased GMD relative to HC in multiple regions including the left 
temporal lobe, right midbrain, left thalamus, right cerebellum, and right insula 
(Table 1-2). BCS did not show any regions of increased GMD relative to HC. 
Functional imaging revealed relatively decreased working memory-related brain 
activation in BCS compared to HC in the right precuneus and left middle 
temporal gyrus. No areas were associated with relatively greater activation in 
BCS.  
 
3-back task performance and reaction times, cognitive testing, self-reports, and 
comet assay 
Performance accuracy and reaction times for the 3-back task did not differ 
between groups. BCS scored lower than HC on the memory domain on 
neuropsychological testing (F (1, 45) = 4.20, p = 0.046). The BCS and HC groups 
also differed on the FACT-COG (F (1, 45) = 8.45, p = 0.006) and MASQ (F (1, 
45) = 9.61, p = 0.003) self-report measures, with BCS reporting more cognitive 
complaints on both measures. Oxidative DNA damage was increased in BCS (F 
(1, 45) = 4.00, p = 0.052) (Table 1-1).  
 
Relationship of imaging to other measures 
Within the BCS group, overall neuropsychological function and all but two 
domains were uncorrelated with GMD in the mean of the regions showing 
between-group differences. The learning and memory domain scores, however, 
were negatively correlated with GMD (r = -0.639, p = 0.001 and r = -0.647, p = 
0.001, respectively). Increased oxidative damage was associated with lower 
GMD in BCS (r = -0.508, p = 0.011, Figure 1-3). Activation did not correlate with 
any other measure. Within the HC group, no significant correlations were found.  
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Figure 1-3 Oxidative DNA damage in breast cancer survivors (BCS) as 
measured by comet assay of peripheral lymphocytes vs. mean gray matter 
density (GMD) of clusters in which BCS showed relatively decreased GMD 
compared to healthy controls (HC). 
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Discussion  
This multimodal MRI study of long-term BCS found PCI associated with both 
structural and functional changes on brain MRI. Regional changes on imaging 
were in turn related to neuropsychological performance. Furthermore, a plasma 
biomarker showed increased oxidative DNA damage in BCS compared to 
controls which was also inversely associated with structural changes. 
GMD was positively correlated with PCI in distributed brain regions with the 
largest clusters in the frontal lobes. This suggests that frontal gray matter 
recovers over time after an initial chemotherapy insult, as indicated by two prior 
prospective studies [33, 34]. Working memory-related brain activation was 
inversely associated with PCI in a region proximal to the largest structural finding. 
The convergence of structural and functional changes in the frontal region is 
consistent with prior reports of changes in executive cognitive functions after 
chemotherapy [3-6, 159] as well as retrospective [47, 49] and prospective [45] 
functional neuroimaging studies. Results of previous functional imaging studies in 
breast cancer patients have been interpreted as showing compensatory 
hyperactivation in similar frontal regions [44-46, 129]. The present results 
suggest that frontal hyperactivation diminishes over time, becoming less 
necessary as structural recovery proceeds. Alternatively, decreased activation 
with a longer PCI may reflect a failure of compensatory brain activation over time. 
Although neuropsychological performance could potentially help address this 
issue, the current study cannot differentiate between these mechanisms in the 
absence of substantial cognitive deficits after 6 years. Alterations in 
compensatory processes over time have been observed in other cognitive 
disorders. For example, in early, higher functioning stages of mild cognitive 
impairment (MCI), patients show hippocampal and prefrontal memory-related 
hyperactivation, and activation in these regions decreases as cognitive 
processes decline [31, 32]. 
 
Comparisons between BCS and controls indicated decreases in GMD and 
activation in left middle temporal gyrus. Taken together, the structural and 
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functional findings indicate an incomplete recovery after an average of 6.4 years 
post-treatment. This is generally consistent with previous GMD findings at a 
range of PCIs [36-38] as well as fMRI reports of hypoactivation 5-10 years after 
chemotherapy in BCS [47, 49] . Of note, there is also evidence for increased 
blood flow on 15O-H2O during a memory task an average of 5-10 years after 
chemotherapy [43]. 
 
Relationships among imaging and cognitive variables are a particularly 
interesting aspect of this study that increases the potential clinical significance of 
our findings. Greater GMD in a right frontal cluster derived from a voxelwise 
regression with PCI was associated with better global neuropsychological 
function. GMD clusters derived from between-group imaging analyses showed 
an unexpected negative correlation between GMD and learning and memory 
scores.  
 
DNA damage in cancer patients is attributable to multiple factors, including 
cancer-related inflammation and oxidative stress, deficits in DNA repair 
mechanisms, and treatment-related insult [10]. Chemotherapeutic regimens can 
damage DNA in several ways [10, 160]. Direct DNA damage may occur as a 
result of the mechanism of action of a drug; for example, doxorubicin intercalates 
with DNA, causing strand breaks. Introduction of chemotherapeutic agent into a 
cell can also lead to generation of free radicals, resulting in oxidative damage. 
Substantial increases in both oxidative and direct DNA damage measured via 
peripheral lymphocyte comet assay have been reported from before to shortly 
after chemotherapy (1-2 weeks), and both oxidative and direct DNA damage 
were increased in BC patients relative to HC before treatment initiation [130]. In 
the present study, the increased oxidative but not direct DNA damage in BCS an 
average of 6 years post-chemotherapy relative to HC may suggest that oxidative 
damage is longer-lasting in this population. However, lack of correlation between 
oxidative DNA damage and PCI suggests a variable time course. Increased 
oxidative DNA damage in BCS was associated with decreased GMD in clusters 
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derived from between-group VBM analyses. This is an interesting finding with 
implications for the mechanism of chemotherapy-related brain changes, and 
warrants further investigation. Notably, increases in oxidative and direct DNA 
damage measured via peripheral lymphocyte comet assay have been also been 
reported in Parkinson’s disease [161] as well as both mild cognitive impairment 
and Alzheimer’s disease [162], suggesting that a link between oxidative DNA 
damage and neurodegeneration may be a common phenomenon. 
 
Limitations of the present study include a retrospective, cross-sectional design 
that does not permit firm conclusions with regard to change over time. Our 
patient cohort had a history of several different chemotherapy regimens, although 
many agents were common across patients. Sample size does not allow for 
differentiation of effects of individual regimens. Further, our BCS experienced a 
range of time courses and types of endocrine treatments, which have been 
shown to affect cognition differentially from chemotherapy [118, 119, 163], and a 
majority of this cohort was using these therapies at the time of the study. Cohort 
size does not permit conclusions about these effects of these therapies.  
 
To our knowledge this is the first imaging study of the effects of PCI on brain 
structure and function. We employed multi-modal MRI in concert with 
neuropsychological testing, cognitive self-report and biomarkers to examine the 
relationship among these variables, and found points of anatomic convergence. 
The potential clinical significance of imaging findings was underscored by 
association with cognitive measures. The link between neuroimaging variables 
and peripheral oxidative DNA damage may provide a direction for further 
mechanistic experiments. Prospective multi-modal investigations of treatment 
and survivorship will continue to be important as will recruitment of larger cohorts 
to enhance statistical power and generalizability. Multi-center collaborations may 
be required to achieve sufficient recruitment, which has proven difficult in this 
population. Although challenges remain to fully understand the time course of 
cognitive and biological changes after chemotherapy, the present study 
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demonstrates the important role that PCI may play in neural outcomes after 
chemotherapy. 
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Chapter 2: Chemotherapy-induced amenorrhea: a prospective study of 
brain activation changes and neurocognitive correlates  
Chemotherapy-induced amenorrhea (CIA) often occurs in pre- and peri-
menopausal BC patients, and while cancer/chemotherapy and abrupt estrogen 
loss have separately been shown to affect cognition and brain function, studies of 
the cognitive effects of CIA are equivocal, and its effects on brain function are 
unknown. Functional MRI (fMRI) during a working memory task was used to 
prospectively assess the pattern of brain activation and deactivation prior to and 
one month after chemotherapy in BC patients who experienced CIA (n=9), post-
menopausal BC patients undergoing chemotherapy (n=9), and pre- and post-
menopausal healthy controls (n=6 each). Neurocognitive testing was also 
performed at both time points. Repeated measures general linear models were 
used to assess statistical significance, and age was a covariate in all analyses. 
We observed a group-by-time interaction in the combined magnitudes of brain 
activation and deactivation (p = 0.006): the CIA group increased in magnitude 
from baseline to post-treatment while other groups maintained similar levels over 
time. Further, the change in brain activity magnitude in CIA was strongly 
correlated with change in processing speed neurocognitive testing score (r=0.837 
p=0.005), suggesting this increase in brain activity reflects effective cognitive 
compensation. Our results demonstrate prospectively that the pattern of change 
in brain activity from pre- to post-chemotherapy varies according to pre-treatment 
menopausal status. Cognitive correlates add to the potential clinical significance 
of these findings. These findings have implications for risk appraisal and 
development of prevention or treatment strategies for cognitive changes in CIA.  
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Introduction 
Cancer and its treatments have been linked to cognitive dysfunction, particularly 
in the executive function, working memory, and processing speed domains [6]. 
Approximately 80% of pre- or peri-menopausal breast cancer (BC) patients 
undergoing current widely used chemotherapy (CTx) regimens 
(cyclophosphamide and doxorubicin, with or without a taxane) experience 
chemotherapy-induced amenorrhea (CIA) in the months immediately following 
CTx [102-105]. CIA results from disruption of normal ovarian follicular maturation, 
leading to markedly decreased systemic estrogen levels [106], and is associated 
with increased survival [102, 107]. As abrupt estrogen loss in pre-menopausal 
women has been linked to cognitive dysfunction [61], it is plausible that CIA may 
lead to increased detrimental effects of CTx compared to women who undergo 
CTx but not CIA (usually BC patients post-menopausal before CTx). Indeed, 
prospective studies have shown decline or failure to improve with practice in 
multiple cognitive domains in patients undergoing CIA compared to patients 
undergoing CTx but not amenorrhea [109, 110], although other studies found no 
such effect [111-113]. Timing of measurements appears to play a role. 
 
Prospective functional neuroimaging has the power to observe, in the face of a 
neural insult such as CTx or estrogen loss, how the brain might compensate (in 
the context of maintained cognitive performance), or fail to adapt (in the context 
of decreased performance). We recently showed pre-treatment frontal 
hyperactivation in BC during a working memory task, with a decrease in 
activation in this region one month post-CTx accompanied by decreased working 
memory performance [45]. Performance and activation returned to higher levels 
one year later. The neural effects of abrupt estrogen loss in pre-menopausal 
women have been studied prospectively with gonadotropin hormone releasing 
hormone (GnRH) agonists. These studies generally show that estrogen ablation 
is associated with reversibly decreased task-related activation [92-94, 164]. 
However, the neural effects of CIA remain unclear.  
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The aim of this study was to prospectively measure global changes in working 
memory-related activation and deactivation, before cancer treatment and one 
month post-CTx completion. During a cognitive task, brain activation increases in 
“task-positive network” regions, while task-induced deactivation occurs in the 
anatomical regions of the “default mode network” (DMN) in a reallocation of 
neural resources [27]. Both activation and deactivation are important in cognition, 
and both are affected by normal aging as well as pathological conditions. 
Drawing on participants in our previous prospective fMRI study of BC patients 
[45], we examined working memory-related activation and deactivation in BC 
patients who underwent CIA (i.e., pre- or perimenopausal patients) and patients 
who were post-menopausal at CTx initiation. Pre- and post-menopausal healthy 
control (HC) groups were imaged at yoked intervals. We hypothesized that the 
CIA profile of activation and deactivation during a working memory task would be 
distinct from that of HC or post-menopausal CTx, and these changes over time 
would be correlated with changes seen in neurocognitive performance.  
 
Methods 
Participants 
Appropriate cases were selected from our previous fMRI study [45] to fit the 
following categories: post-menopausal BC patients undergoing CTx (n=9), pre- or 
peri-menopausal BC patients undergoing CTx (n=9), pre- and post-menopausal 
HC (n=6 each). Scans and neuropsychological measures were collected prior to 
any cancer treatment (baseline; BL) and one month post-CTx completion (M1) or 
yoked intervals for HC. 
 
Patients had stages I, II, or IIIA BC treated with standard-dose AC or AC-T CTx 
regimens (Table 2-1). Exclusion criteria included prior cancer or cancer treatment 
and medical, neurological, and psychiatric risk factors known to affect brain 
structure or function, as detailed previously [33]. Depressive symptoms and 
anxiety were assessed with the Center for Epidemiologic Studies-Depression 
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Scale (CES-D) [152] and the State-Trait Anxiety Inventory-State subscale (STAI-
S) [153].  
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Table 2-1 Demographics and cancer treatment information 
 
Chemotherapy-
induced 
amenorrhea (n=9) 
Healthy 
control pre-
menopausal 
(n=6) 
Chemotherapy 
post-
menopausal 
(n=9) 
Healthy 
control post-
menopausal 
(n=6) 
Age (years)** 
45.3±5.8 
(range 35-55) 
44.8±4.0 
(range 37-48) 
58.7±4.4 
(range 53-69) 
55.2±4.0 
(range 50-59) 
Education (years) 14.8±1.8 15.8±1.3 15.2±3.3 15.8±2.0 
Handedness 
(R:L,A) 
8:1 4:2 8:1 6:0 
Full Scale IQ 
Estimate [158] 
110.5±6.8 113.8±3.0 112.7±6.6 114.8±2.9 
CES-D 
BL 8.2±9.0 7.6±6.1 8.0±7.4 2.3±1.6 
M1 11.0±11.5 7.2±5.8 9.8±9.2 4.2±4.8 
STAI-S 
BL 34.1±14.0 28.6±8.6 29.0±9.1 25.2±7.5 
M1 35.7±18.2 28.0±5.3 28.4±8.8 27.5±11.9 
Psychiatric 
Medications   
BL 
2 (1 buspirone and 
desipramine, 1 
zolpidem) 
0 
2 (1 venlafaxine 
and buspirone, 1 
fluoxetine) 
0 
M1 
3 (1 buspirone and 
desipramine, 1 
zolpidem, 1 
sertraline) 
0 
2 (1 venlafaxine 
and buspirone, 1 
fluoxetine) 
0 
BL-M1 interval 
(days) 
153±45 167±36 181±78 206±51 
Cancer stage 
2 stage I 
5 stage II 
2 stage IIIa 
 
2 stage I 
7 stage II  
Chemotherapy 
regimen 
7 AC-T, 1 AC-T 
plus trastuzumab, 1 
AC 
 
7 AC-T, 2 AC 
 
Hormonal 
medication 
BL 
1 estradiol (for 
perimenopausal 
symptoms) 
0 0 
4 hormone 
replacement 
therapy 
M1 2 tamoxifen 0 
1 tamoxifen, 1 
aromatase 
inhibitor 
2 hormone 
replacement 
therapy 
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Menstrual Status 
Periods regular 
throughout study 
0 6 0 0 
Post-menopausal 
(>6 months) 
throughout study 
0 0 9 6 
Periods irregular at 
BL, amenorrhea ≥6 
months at M1 
3 0 0 0 
Periods regular at 
BL, amenorrhea ≥6 
months at M1 
4 0 0 0 
** p<0.001 overall ANOVA; in post-hoc Tukey tests, both pre-/peri-menopaual 
groups less than both postmenopausal groups; both pre-/peri- and post-
menopausal groups not different than each other 
CES-D: Center for Epidemiologic Studies-Depression Scale [152] 
STAI-S: State-Trait Anxiety Inventory-State subscale [153] 
BL: baseline 
M1: one month post-chemotherapy completion or yoked interval 
AC: Doxorubicin and cyclophosphamide 
AC-T: Doxorubicin, cyclophosphamide, and a taxane 
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Written informed consent was obtained according to the Declaration of Helsinki 
under a protocol approved by the Dartmouth College Committee for the 
Protection of Human Subjects. 
 
MRI Scans 
Scans were acquired on a 1.5T GE Signa LX scanner with echospeed gradients 
and standard head coil. A gradient-echo, echo-planar sequence provided whole 
brain coverage for fMRI: TR=2500ms, TE=40ms, FOV=24cm, NEX=1, 29 
interleaved 5mm thick contiguous sagittal slices, yielding a 64x64 matrix with 
3.75mm2 in-plane resolution. Structural scans were acquired to rule out incidental 
pathology and for the previously reported gray matter density analysis [33]. 
An auditory-verbal “N-back” task was used as in our previous study [45]. During 
scanning participants heard a string of consonant letters (except L, W, and Y) 
presented one every three seconds. Task conditions were 0-, 1-, 2-, and 3-back, 
in a blocked design. For each consonant participants used a button press device 
to signify whether the current letter was a match (i.e., was the same as the 
designated target or the letter presented 1, 2, or 3 back in the sequence) or a 
non-match. Each condition was presented in 27-second epochs preceded by 
three seconds of instruction (e.g., “the match is one back”). The four 
experimental conditions were each presented three times in pseudo-random 
order for a total of 12 task blocks. Participants rehearsed a practice version of the 
task prior to scanning to ensure comprehension of task demands. Stimuli were 
presented through an MRI compatible headphone system, and programmed in 
Presentation software (Neurobehavioral Systems, Inc., Albany, CA), which 
recorded response accuracy and reaction times. 
 
Using raw scan data, spatial realignment using a six parameter model was 
performed in SPM5. Realignment parameters were entered as covariates at the 
subject level, and volumes were normalized into MNI space, resampled to 2mm3 
voxels, and smoothed to a FWHM of 8mm. Statistical parametric mapping on a 
voxel-by-voxel basis was conducted using a general linear model (GLM) 
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approach. Contrast images comparing pairs of working memory load conditions 
(e.g., 3-back > 0-back) were created for each subject.  
 
To derive numerical values for activation and deactivation during the 3-back task, 
all 3-back > 0-back contrast images were entered into a one-sample t-test in 
SPM5. Maps were created for activation (contrast vector 1; i.e., 3-back > 0-back) 
and deactivation (contrast vector -1; i.e., 0-back > 3-back) at pcrit = 0.05, cluster 
minimum size (k) = 10 voxels. MarsBar v. 0.42 [165] was used to extract mean 
values for each participant’s activation and deactivation at both time points.  
 
Neurocognitive Testing Domains 
Raw neurocognitive test scores were normalized using the mean and standard 
deviation of the larger HC group from which HC subjects for the current study 
were drawn (demographic data regarding the larger cohort can be found in [33]). 
Domain scores were created for each subject by averaging the z-scores of the 
included tests, and were then adjusted for age using the entire sample of the 
current study. The verbal domain was calculated using the Wide Range 
Achievement Test (WRAT-3) reading score [166], the Wechsler Abbreviated 
Scale of Intelligence (WASI) Vocabulary score [146], and the Delis-Kaplan 
Executive Function System (D-KEFS) Verbal Fluency Test phonemic and 
semantic trial scores [147]. The verbal memory domain consisted of the 
California Verbal Learning Test total and delayed free recall scores [167] and the 
Craft story immediate and delayed recall scores [141]. The visual memory 
domain was the Brown Learning Test initial learning trials and delayed recall 
score [168]. The working memory score consisted of the Rao Paced Auditory 
Serial Addition Test (PASAT) 2 and 3 minute trial totals [144]. The processing 
speed score comprised the WAIS-III Digit Symbol-Coding score [143], the left- 
and right-hand grooved pegboard times [149], completion times from D-KEFS 
Trail Making Test trials 1-5, and the D-KEFS Color-Word Interference Test color 
naming, word reading, and color-word interference trials. The sorting domain was 
the D-KEFS Sorting Test number of correct sorts and the free sorting and 
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recognition trial description scores. The distractibility domain was the Gordon 
Continuous Performance Task (CPT) distractibility trial total correct and false 
positive scores, while the reaction time domain was the average of the 
distractibility and vigilance trials reaction times. The global score was the 
average of all the above domains as well as the WASI Block Design score. 
 
Statistical Analyses 
One-way ANOVA with Tukey post-hoc tests were used to examine between-
group effects of age, education, IQ estimates, and BL-M1 interval, while chi-
square examined handedness distribution. Experimental measures, including 
fMRI activation and deactivation, neuropsychological tests, 3-back task 
performance and reaction times, and depression and anxiety scores were 
assessed using a repeated measures general linear model in SPSS 19 with 
factors of group and time. Age covariates were used in imaging analyses, while 
neuropsychological measures were pre-adjusted for age. Group-by-time 
interactions from these analyses were examined, as well as main effects of group 
and time. Absolute values of activation and deactivation were summed at each 
time point to create a measure of total change in neural activity and analyzed 
using the same repeated measures model. Pearson correlations were used to 
assess relationships between changes in imaging variables and 
neuropsychological values.  
 
Results 
Demographics, psychological state, hormonal status and cancer treatment data 
are provided in Table 2-1. As expected, groups differed in age, with both post-
menopausal groups significantly older than both pre-menopausal groups at 
baseline (overall ANOVA p<0.001; post-hoc Tukey tests p<0.05) 
 
Education, handedness, estimated IQ, and BL-M1 interval did not differ between 
groups. CES-D and STAI-S mean scores were well below clinical thresholds and 
did not show main effects of group or time or group-by-time interactions. Several 
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cancer patients were using psychiatric medications at each study visit, with little 
change in medication regimens between BL and M1. Cancer stage and CTx 
regimens were similar between groups. 
 
All post-menopausal HC and CTx participants reported amenorrhea >6 months at 
study entry, and all pre-menopausal HC had regular periods at study entry (Table 
2-1). In the CIA group, 4 patients reported regular periods and 3 patients 
reported irregular periods at study entry, and all of these reported amenorrhea >6 
months related to CTx at M1. Menstrual status was unavailable for 2 CIA 
patients, but they were placed in this group based on their ages of 44 and 45 at 
study entry, as all HC under 50 in this cohort were pre-menopausal. For 
hormonal medications, several post-menopausal patients reported using 
hormonal replacement therapy at each visit (4 at BL, 2 at M1). One 55-year-old 
CIA participant (the oldest in this group) was using estrogen for perimenopausal 
symptoms at BL but not at M1. No cancer patients were using antiestrogen 
treatments at BL, but 2 patients in each cancer group had started these 
treatments at M1. 
 
Figure 2-1 depicts the activation and deactivation regions of interest used to 
derive values for each participant at BL and M1. Figure 2-2a shows mean values 
of activation and deactivation for each group at BL and M1. Repeated measures 
ANOVA with an age covariate did not show any significant main effects or 
interactions for either activation or deactivation. Repeated measures ANOVA on 
the summed magnitudes of activation and deactivation for the four groups with 
an age covariate revealed a significant group-by-time interaction (p=0.006). In 
contrast to the other groups, the CIA group showed an increase in the summed 
magnitudes of activation and deactivation from BL to M1 (Figures 2-2b, 2-2c), 
and this change was statistically significant (p=0.011). There was also a 
significant effect of time (p=0.046), with an overall pattern of increased 
magnitudes from BL to M1 and a time-by-age interaction (p=0.047) in which 
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younger participants tended to increase in magnitude over time (driven by the 
CIA group). 
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Figure 2-1 Working memory-related activation (3-back > 0-back contrast)) (a) 
and deactivation(0-back > 3-back contrast) (b) regions of interest derived from 
main effects of all groups’ baseline and one month post-chemotherapy scans; 
pcrit=0.05, minimum cluster extent (k)=10. 
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Figure 2-2a Working memory-related total activation and deactivation at baseline 
(BL) and 1 month post-chemotherapy (M1) (arbitrary units; mean±SD). 
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Figure 2-2b Summed magnitudes of activation and deactivation at BL and M1; 
group-by-time interaction is statistically significant (p=0.006), with only the CIA 
group showing change over time (p=0.011). 
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Figure 2-2c Change between BL and M1 in summed magnitudes of activation 
and deactivation.   
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In-scanner 3-back task performance and reaction times did not differ between 
groups or over time (Table 2-2). 
 
Group means of neuropsychological testing domains are shown in Table 2-2. A 
main effect of time was present for most domains at p ≤0.01.This reflected an 
overall tendency toward improved performance at M1, likely due to practice 
effects. Main effect of group was not statistically significant in any domain. 
Interestingly, trends toward group-by-time interactions were present in the verbal 
(p=0.073) and visual memory (p=0.098) domains. In both of these domains, all 
groups showed improved performance from BL to M1 except for the CTx post-
menopausal group, whose performance decreased between sessions.  
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Table 2-2 Neurocognitive testing and in-scanner task results  
 Chemotherapy- 
induced 
amenorrhea 
(n=9) 
Healthy 
control pre-
menopausal 
(n=6) 
Chemotherapy  
post-
menopausal 
(n=9) 
Healthy 
control 
post-
menopausal 
(n=6) 
Neurocognitive Testing Domains 
Verbal^ 
BL -0.339±0.837 0.211±0.581 0.173±1.074 -0.264±0.976 
M1 -0.230±0.722 0.370±0.662 0.029±0.956 -0.029±0.723 
Verbal Memory  
BL -0.271±1.029 -0.335±0.723 -0.345±0.932 0.380±0.767 
M1 -0.311±0.881 -0.092±0.495 -0.198±0.893 0.297±1.011 
Visual 
Memory**^ 
BL -0.241±1.42 0.179±0.607 0.222±0.549 0.145±1.336 
M1 0.584±1.548 0.848±0.778 0.135±0.618 1.071±1.615 
Working 
Memory** 
BL 0.125±0.965 0.019±0.290 0.778±0.718 0.123±0.977 
M1 0.659±1.157 0.421±0.585 1.091±0.920 0.312±0.670 
Processing 
Speed* 
BL 0.123±0.940 0.132±0.415 0.061±0.405 0.138±0.401 
M1 0.292±0.981 0.355±0.384 0.064±0.638 0.255±0.232 
Sorting** 
BL -0.598±0.878 -0.035±0.912 -0.360±0.988 0.135±0.827 
M1 -0.011±1.079 0.613±0.659 -0.431±1.168 0.566±1.345 
Distractibility** 
BL -1.276±1.940 -0.430±0.750 -0.475±2.213 0.468±1.342 
M1 -1.808±2.296 -0.438±0.651 -1.318±3.702 0.812±0.531 
Reaction Time** BL 0.319±0.701 -0.446±1.173 0.021±0.788 0.113±0.710 
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M1 0.552±0.508 -0.097±1.318 0.291±0.637 0.407±0.628 
Global** 
BL -0.320±0.760 -0.079±0.518 -0.076±0.713 0.190±0.710 
M1 -0.102±0.863 0.240±0.439 -0.096±0.982 0.447±0.569 
In-scanner 3-back task 
3-back score (% 
corrected for 
guessing) 
BL 65.3±27.3 74.4±7.8 62.1±24.6 78.5±16.1 
M1 65.3±27.3  74.3±12.7 63.2±25.0 67.1±12.7 
Reaction time 
(seconds) 
BL 1.20±0.31 1.01±0.13 1.01±0.20 1.15±0.10 
M1 1.19±0.34 0.97±0.10 1.09±0.15 1.16±0.08 
** main effect of time p≤0.01 
* main effect of time p≤0.05 
^ group-by-time interaction trend p<0.10 
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To assess the functional significance of the increased magnitude of neural 
activity in CIA, we tested for correlations between the activity change in this 
group and change in neuropsychological domain scores. A significant positive 
correlation emerged in the processing speed domain (r=0.837, p=0.005, survives 
Bonferroni threshold for 9 domains (p=0.045 after correction; Figure 2-3). The 
positive valence indicates that increased magnitude of neural 
activation/deactivation between BL and M1 is associated with improvement in 
processing speed scores. No other CIA activity change-neurocognitive domain 
correlations were statistically significant. 
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Figure 2-3 Correlation of change in summed magnitude of activation and 
deactivation with change in processing speed neuropsychological testing domain 
scores from baseline to one month post-chemotherapy in chemotherapy-induced 
amenorrhea (CIA) (r=0.837, p=0.045 after Bonferroni correction for 9 
neuropsychological domains). 
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Discussion 
Our results demonstrate prospectively that the pattern of change in brain activity 
from pre- to post-CTx varies according to pre-treatment menopausal status. BC 
patients who underwent CIA showed increased magnitudes of activation and 
deactivation from pre- to post-CTx, while CTx post-menopausal and both HC 
groups did not. In the context of maintained 3-back task performance, this may 
indicate effective compensatory neural activity in the CIA group. Age, an 
inevitable between-group confound in this type of analysis, was included as a 
covariate, suggesting that these effects are due to CIA itself. We found no 
evidence for the negative cognitive effect of CIA that has been observed in some 
studies [109, 110] but not others [111-113].  
 
Relationships between brain changes and behavioral measures increase the 
potential clinical significance of our findings. CIA-related change in neural activity 
was highly correlated with improvement in neurocognitive processing speed 
scores from BL to M1, suggesting that this adaptation is functional. Processing 
speed, in addition to working memory and executive function, is one of the 
domains most often implicated in cancer- and treatment-related cognitive 
dysfunction [6].  
 
The current results are consistent with the interpretation that the neural stress of 
CIA’s abrupt decrease in estrogen, in addition to CTx itself, requires alterations in 
brain activity to maintain cognitive function. In light of evidence that both 
activation [28] and deactivation [29] increase parametrically with task demand, 
these results suggest that after CTx, the CIA brain responds to the same 3-back 
task as if it is more difficult. A similar phenomenon of effective compensatory 
activation has been observed in mild cognitive impairment (MCI) in older adults: 
in the early, higher functioning stages of MCI, patients show hippocampal and 
prefrontal hyperactivation during memory tasks compared to cognitively normal 
older adults, while activation decreases in later stages of MCI as cognitive 
functioning declines [31, 32]. 
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Interestingly, in neuropsychological testing, the post-menopausal CTx group was 
unable to maintain performance in the post-CTx visit, while in all other groups 
scores improved between BL and M1 in the verbal and visual memory domains 
(in non-significant trends for group-by-time interactions). These domains involve 
different neural circuitry than the working memory scanner task and have not 
been especially previously implicated in CTx-related cognitive dysfunction, but 
the lack of increase in neural activity in the post-menopausal CTx group may be 
related to this decreased neurocognitive performance post-treatment. As 
estrogen loss reduces neuroplasticity, and longer duration of estrogen 
deprivation (i.e., more time after menopause) is associated with worse outcomes 
[57], the lack of change in brain activity may be related to reduced neuroplastic 
adaptation to CTx in the post-menopausal brain. This result is also consistent 
with a recent longitudinal study [159] which found that older age was related to 
increased risk for cognitive dysfunction after CTx, particularly in the context of 
processing speed domain and lower cognitive reserve (although no effects of 
pre-treatment menopausal status were observed). It should be noted, however, 
that the current study represents a small sample size relative to most cognitive 
studies, and the statistical effects are consequently modest. Follow-up in larger 
cohorts is warranted. 
 
While there are no neuroimaging studies of CIA with which to compare the 
current results, neuroimaging studies of both cancer/CTx and estrogen 
suppression in pre-menopausal women do exist. In cancer and CTx, BC patients 
have shown pre-treatment frontal hyperactivation [44, 45] that is attenuated one 
month post-CTx but remains hyperactive one year later [45]. Task performance 
tended to decrease along with the attenuation of hyperactivation at one month 
and return to higher levels one year later [45]. Studies of longer-term survivors 
with a history of CTx have demonstrated lower activation in task-related regions 
[47, 49]. Prospective studies of pre-menopausal women who undergo abrupt 
estrogen suppression with gonadotropin releasing hormone (GnRH) agonists 
have shown globally attenuated task-related blood flow on PET in the context of 
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maintained task performance [94], and decreased frontal fMRI activation during 
memory encoding with a trend toward worse performance on the subsequent 
recognition test [92]. It is notable that in the GnRH agonist studies, estrogen is 
still being suppressed at the time of scanning, while at M1 in the current study, 
ovarian function may be starting to resume after CIA and several patients were 
using tamoxifen, which also affects estrogen function. All of the above studies 
measured regionally specific task-related activation, while the current study 
focuses on global levels of activation and deactivation, so direct comparison is 
difficult.  
 
The effects of cancer and CTx on cognition and brain activity likely involve 
multiple biological pathways [10], and the present results contribute to a better 
understanding of one key pathway, hormonal changes. Possible mechanisms for 
CTx-related cognitive dysfunction, including oxidative stress and genetic factors, 
overlap with those for those thought to be involved in the deleterious effects of 
estrogen loss [10, 169, 170], suggesting possible compounding effects.  
 
This study has several strengths. To our knowledge, this is the first neuroimaging 
study of CIA. The study is prospective, increasing confidence in attribution of 
brain effects to CIA. Two groups of HC were employed to match the CIA and 
post-menopausal CTx groups. Our analyses employed either an age covariate or 
data pre-adjusted for age, minimizing the effects of this potential confound. 
Comprehensive neuropsychological testing was conducted in order to determine 
domain-specific effects of treatment. Finally, the strong correlation in CIA 
between changes in neural activity and processing speed is promising for the 
behavioral relevance of these results. 
 
This study also has several limitations. Pre- and peri-menopausal BC patients 
were included in the CIA group, potentially increasing variability. Several of our 
BC patients used antidepressants and post-CTx anti-estrogen therapy, which is 
difficult to avoid in this population. We relied on self-reported menstrual status at 
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each session rather than hormone levels; future work correlating cognitive and 
imaging variables with hormone levels would be informative.  
 
Subsequent studies should follow the effects of CIA longitudinally. While 80% of 
pre-and peri-menopausal BC patients experience CIA in the months immediately 
following CTx [102-105], only 20-60% remain amenorrheic 6-12 months later 
[105, 114, 115]. Complicating matters, tamoxifen has been shown to potentiate 
CIA [115], and post-menopausal CTx comparison groups will likely be using 
aromatase inhibitors which may have different neural effects than tamoxifen. 
While estrogen is neurotrophic and neuroprotective in vitro, the effects of 
estrogen loss (and replacement) on the human brain are complicated and 
controversial [62, 114], and CIA is no exception. Despite these complications, it 
will be important to determine the neural effects of CIA throughout survivorship. 
Other types of fMRI analyses (voxelwise, resting state, etc.) will also be 
informative, as estrogen influences both structural and functional connectivity 
[171]. While BC patients cannot be treated with any agent that is an estrogen 
agonist to breast tissue, future intervention with other agents, such as specially 
designed “neuro-SERMs” [127, 172], which might be estrogen antagonists to 
breast and uterus and estrogen agonists to brain and bone, may prove beneficial. 
The current findings have implications for risk appraisal and development of 
prevention or intervention strategies for cognitive changes in CIA. 
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Chapter 3: ESR1 variation and brain structure in cognitively normal older 
adults: effects of sex, brain region, and APOE-ε4 allele 
Neural effects of estrogen are thought to contribute to sex differences in 
prevalence and presentation of psychiatric and neurological disorders. Variation 
in ESR1 (coding for estrogen receptor-α (ER-α)), particularly in the single 
nucleotide polymorphisms (SNPs) rs2234693 and rs9340799, has been found to 
be related to many of these disorders, but little work has focused on its 
relationship to brain structure. We examined MRI scans and ESR1 genotypes 
from 195 cognitively and psychiatrically healthy older adults recruited as part of 
the Alzheimer’s Disease Neuroimaging Initiative. Whole-brain voxel-based 
morphometry, cortical thickness analyses, and automated medial temporal 
volumetry were used to probe brain-genotype relationships. Voxel-based 
morphometry revealed an interaction in which males carrying a T allele of 
rs2234693 or an A allele of rs9340799 showed greater gray matter (GM) density 
in regions distributed throughout the brain, while females carrying a C allele of 
rs2234693 or a G allele of rs9340799 showed greater GM density. Cortical 
thickness analysis showed similar results. These effects were not modulated by 
APOE-ε4 carrier status. Right amygdala volumes, with trends for left amygdala 
and left hippocampus, were significantly greater in females with the rs9340799 
GG genotype compared to the AA genotype. Furthermore, in females, APOE-ε4 
carrier status interacted with rs2234693 genotype with regard to amygdala 
volumes. This study is the first to demonstrate that, even in cognitively and 
psychiatrically normal older adults, genetic variation in estrogen receptors affects 
brain morphology in ways that differ by sex, brain region and APOE-ε4 carrier 
status.  
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Introduction 
Neural effects of estrogen are thought to contribute to sex differences in 
prevalence and presentation of psychiatric disorders, including depression [173], 
schizophrenia [174], and others [175], and neurological disorders such as 
Parkinson’s disease [51] and Alzheimer’s disease (AD) [52, 176, 177]. Estrogen 
is critically involved in memory and affective functions [175]. On a cellular level, 
estrogen is neuroprotective, interacting with a variety of neuroplastic processes 
[57], growth factors [64], and neurotransmitters [65]. Estrogen also influences 
pathways important in AD pathogenesis, including amyloid, tau, and 
acetylcholine synthesis [63, 67-69, 178]. While most circulating estrogen in 
premenopausal females is produced by the ovaries, estrogen is produced 
throughout life in both sexes by neurons, astrocytes, and cerebrovascular 
endothelial cells [65]. In men, brain aromatase converts circulating testosterone 
to estrogen, which is important in cognition [50]. Neural estrogen receptors are 
widely expressed in both sexes. 
 
Estrogen receptor genetic variation can alter the downstream neural effects of 
estrogen, and relationships between this variation and clinical phenotypes have 
been well documented. Polymorphisms in ESR1, the gene coding for estrogen 
receptor-α (ER-α), have been associated with a number of psychiatric disorders 
(see [79] for review), including postmenopausal depression [179], premenstrual 
dysphoric disorder [180], methamphetamine-induced psychosis in men [181], 
childhood-onset mood disorders in girls [182], and obsessive-compulsive 
disorder [183] and schizophrenia in both sexes [184]. ESR1 variation has been 
associated with age of onset or risk of AD in both sexes [71, 185-188], and ESR1 
genotype may interact with the apolipoprotein E-ε4 (APOE-ε4) allele in 
influencing AD onset [71-73]. Further, in healthy individuals, ESR1 
polymorphisms have also been associated with cognitive function [70] and 
personality traits [189]. Two ESR1 Intron 1 single nucleotide polymorphisms 
(SNPs) rs2234693, previously called PvuII, and rs9340799, or XbaI, have been 
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associated with a wide range of clinical phenotypes, and a considerable number 
of ESR1 studies referenced above include these SNPs.  
 
Despite evidence for ESR1 involvement in many CNS disorders, only one study 
has assessed its relationship to brain phenotypes. den Heijer and colleagues 
[190] studied 468 older adults from the Rotterdam Scan Study, including 25 who 
developed dementia. Manually segmented amygdala volumes were significantly 
associated with rs2234693 and rs9340799 genotype in women but not men, 
regardless of dementia status, with similar trends for hippocampal volumes. 
These medial temporal lobe (MTL) structures are implicated in numerous 
cognitive and psychiatric disorders. 
 
To investigate structural changes throughout the brain associated with ESR1 
variation, we examined MRI scans from 195 cognitively and psychiatrically 
healthy older adults in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
cohort. The current study aimed to: 1) determine, in each sex, the relationship of 
rs2234693 and rs9340799 genotype to gray matter (GM) density throughout the 
brain and automatically traced MTL volumes; 2) examine the relationship of 
these SNPs to cortical thickness; 3) assess the role of APOE-ε4 allele on these 
phenotypes 
 
Methods 
Sample 
Data were obtained from the ADNI database (http://www.loni.ucla.edu/ADNI). 
Data downloaded for 228 cognitively normal participants included baseline 1.5 T 
MRI scans, SNP genotypes, demographics, APOE genotype, and current 
medications. Exclusion criteria for ADNI included recent history of depression, 
bipolar disorder, substance abuse or dependence, and any history of 
schizophrenia. Females were at least two years past menopause or surgical 
sterilization.  
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MRI Processing  
Participants had at least two 1.5T MP-RAGE scans at baseline according to the 
ADNI MRI protocol [191]. As described elsewhere [192], each scan was 
independently processed using two automated techniques: whole-brain voxel-
based morphometry (VBM) [193-195] and segmentation and parcellation using 
FreeSurfer v. 4.01 [196, 197] (http://surfer.nmr.mgh.harvard.edu/). Briefly, image 
processing utilized SPM5 (http://www.fil.ion.ucl.ac.uk/spm/) to create GM density 
maps (1mm3 voxels, smoothed with a 10mm FWHM Gaussian kernel) 
normalized to Montreal Neurological Institute (MNI) atlas space. Two 
independent, smoothed, normalized GM density maps for each participant were 
averaged to create a mean map. Two participants failed VBM segmentation. 
FreeSurfer was used to automatically identify cortical and subcortical tissue 
classes using an atlas-based Bayesian segmentation procedure. Cortical 
thickness values, MTL structure volumes, and total intracranial volume (ICV) 
were extracted for all participants. FreeSurfer values from the two MP-RAGE 
images obtained at the same study visit for each participant were averaged to 
create mean values. Amygdala and hippocampus volumes were adjusted for age 
and ICV. Cortical thickness values were registered to the cortical surface of a 
template created from all ADNI healthy control participants. 
 
ESR1 Genotyping 
Genotyping and quality control were completed using the Illumina Human601-
Quad BeadChip, Illumina BeadStudio 3.2 software (Illumina, Inc., San Diego 
CA), and PLINK v1.06 software [198] (http://pngu.mgh.harvard.edu/purcell/plink/) 
in a protocol described elsewhere [199, 200]. Population stratification analysis 
suggested the advisability of restricting analyses to non-Hispanic Caucasians. 
After the QC procedure, 203 of the 226 participants with usable MRI data 
remained.  
 
As ESR1 rs2234693 and rs9340799 were not included among SNPs genotyped 
on this chip, they were imputed using MaCH [201] 
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(http://www.sph.umich.edu/csg/yli/mach/index.html) and the HapMap2 release 24 
CEU reference sample (individuals of Northern and Western European ancestry) 
[202] (http://hapmap.ncbi.nlm.nih.gov/index.html.en). Imputed genotypes with 
posterior probability for the most likely genotype less than 0.9 were excluded. 
195 participants remained for rs2234693 and 178 for rs9340799. PLINK v.1.07 
was used to calculate linkage disequilibrium between the two SNPs in the study 
population. rs2234693 (PvuII) has a T (p) major allele and a C (P) minor allele; 
rs9340799 (XbaI) has an A (x) major allele and a G (X) minor allele. We will refer 
to the SNPs using rs numbers and allele nucleotides rather than the older PvuII 
and XbaI nomenclature. 
 
VBM Statistical Analyses 
Voxelwise statistical analyses were performed using SPM5. For each SNP an 
omnibus group ANOVA was constructed with factors of sex and genotype (TT, 
CT, or CC for rs2234693; AA, GA, or GG for rs9340799), including age and ICV 
as covariates. A voxel-level critical significance threshold (pcrit) of 0.005 was 
used. With this pcrit, a minimum cluster extent (k) was used to retain only regions 
that survived an uncorrected cluster-level threshold of p≤0.05. Both voxel-level 
and cluster-level significance values are reported to address multiple 
comparisons. Voxel-level significance values represent the probability (under the 
null hypothesis) of finding a voxel with as great or greater a peak statistical 
threshold (T). Uncorrected cluster-level significance values (puncorrected) represent 
the probability (under the null hypothesis) of finding a cluster with as great or 
greater a number of voxels (k). Correction for whole-brain search volume results 
in corrected cluster-level significance values (pcorrected). 
 
Within the omnibus ANOVA, weighted contrast vectors were used to create 
contrast maps showing voxels in which local GM density differed between 
groups. Mean GM density values for each subject were extracted from significant 
clusters using the MarsBaR SPM toolbox [165] (http://marsbar.sourceforge.net). 
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Cortical Thickness: SurfStat 
SurfStat [203] (http://www.math.mcgill.ca/keith/surfstat/) was used to determine 
areas of group difference in cortical thickness, using the same omnibus ANOVA 
and weighted contrast vectors described above for VBM analyses. Correction for 
multiple comparisons used the random field theory (RFT) method at a 0.05 level 
of significance.  
 
Other Statistical Analyses 
Demographic, MTL volume, and APOE-ε4 epistasis analyses were performed in 
PASW Statistics v18.0 (SPSS, Inc., Chicago IL) separately for rs2234693 and 
rs9340799. For most demographic information and all MTL volumes, males and 
females were analyzed separately using one-way ANOVA with a factor of 
genotype; between-sex demographic differences were determined using one-
way ANOVA with a factor of sex. Results were considered significant at p≤0.05, 
and post-hoc Tukey tests were used for pairwise comparisons. Chi-square tests 
were used to compare handedness and APOE-ε4 carrier status among 
genotypes within each sex as well as genotype distributions, handedness, and 
APOE-ε4 carrier status between sexes. Multivariate general linear model 
analysis was used to examine the interaction of APOE-ε4 carrier status and 
ESR1 genotype on brain phenotypes. Factors were ESR1 genotype and APOE-
ε4 carrier status (ε4 present or absent) and dependent variables were mean GM 
cluster values (from VBM) or MTL volumes. To determine the amount of variance 
accounted for by genotype (r2), linear regressions with genotype (number of 
minor alleles: 0, 1, or 2) were performed for mean cluster values from VBM 
analyses and for MTL volumes.  
 
Results 
Participant Characteristics and Genotypes 
Distribution of genotypes between sexes was not significantly different for either 
SNP (chi-square p>0.05). Table 3-1 includes demographic information by sex 
and genotype for each SNP. Males with CC (rs2234693) or GG (rs9340799) 
67 
genotypes showed significantly, although not clinically meaningfully, higher 
Geriatric Depression Scale (GDS) [204] scores (p<0.05). Mini-mental status 
examination (MMSE) [205] scores and Neuropsychiatric Inventory Questionnaire 
(NPI-Q) [206] scores did not differ between genotypes. Educational attainment 
varied between sexes for both SNPs (p<0.001); thus, VBM analyses (which 
included a factor of sex in the omnibus ANOVA) were repeated using an 
education covariate, with the overall pattern of results unchanged.
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Table 3-1 Demographic, cognitive, and psychiatric assessment of participants for 
rs2234693 and rs9340799 separated by sex and genotype. Mini Mental Status 
Exam, Geriatric Depression Scale, and Neuropsychiatric Inventory Questionnaire 
scores were all adjusted for age. P-values represent one-way ANOVA by 
genotype for each sex, except for APOE-ε4 carrier status and handedness, 
which represent chi-square tests. Asterisks denote significant effects of genotype 
(p<0.05). 
rs2234693 (PvuII)  
Gender Male Female  
Genotype TT (pp) CT (Pp) CC (PP) p-
value 
TT (pp) CT (Pp) CC (PP) p-
value 
Between-
gender p 
value 
N 35 51 19  22 47 21   
APOE-ε4 
carriers (%) 
9(26) 14(27) 5(26) 0.983 6(27) 15(32) 4(19) 0.548 0.494 
Handedness R:L 31:4 47:4 17:2 0.845 20:2 45:2 20:1 0.704 0.220 
Age 74.42(0.82) 76.66(0.73) 77.24(1.40) 0.073 77.68(1.23) 76.00(0.63) 76.07(0.48) 0.079 0.977 
Education 
(years) 
17.29(0.34) 16.45(0.41) 17.11(0.59) 0.309 14.41(0.48) 15.51(0.40) 15.48(0.63) 0.250 <0.001 
Mini Mental 
Status Exam 
29.01(0.16) 28.95(0.16) 29.27(0.19) 0.502 29.24(0.21) 29.23(0.12) 29.46(0.16) 0.561 0.059 
Geriatric 
Depression 
Scale 
0.74(0.17) 0.68(0.16) 1.50(1.29) 0.024* 0.74(0.18) 0.96(0.19) 0.79(0.20) 0.713 0.908 
Neuropsychiatric 
Inventory 
Questionnaire 
0.43(0.19) 0.33(0.15) 0.47(0.28) 0.868 0.23(0.11) 0.21(0.07) 0.62(0.27) 0.102 0.566 
rs9340799 (Xbal)  
Gender Male Female  
Genotype AA (xx) GA (Xx) GG (XX) p-
value 
AA (xx) GA (Xx) GG (XX) p-
value 
Between-
gender p 
value 
N 41 48 9  33 38 9   
APOE e4 
carriers (%) 
11(27) 12(25) 3(33) 0.872 9(27) 12(32) 2(22) 0.831 0.435 
Handedness R:L 36:5 45:3 8:1 0.612 30:3 37:1 9:0 0.353 0.220 
Age 74.87(0.78) 77.26(0.77) 77.72(2.00) 0.077 77.17(1.00) 75.51(0.64) 75.31(1.51) 0.304 0.864 
Education 
(years) 
17.10(0.31) 16.75(0.44) 17.00(1.00) 0.822 14.79(0.41) 15.26(0.44) 15.11(1.02) 0.704 <0.001 
Mini Mental 
Status Exam 
29.09(0.14) 28.97(0.15) 29.35(0.24) 0.540 29.28(0.16) 29.28(0.13) 29.10(0.31) 0.846 0.131 
Geriatric 
Depression 
Scale 
0.90(0.20) 0.60(0.14) 1.75(0.52) 0.023* 0.80(0.17) 1.01(0.20) 0.46(0.34) 0.385 0.882 
Neuropsychiatric 
Inventory 
Questionnaire 
0.39(0.16) 0.33(0.16) 0.11(0.11) 0.759 0.24(0.09) 0.26(0.10) 0.57(0.56) 0.523 0.720 
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To ensure that hormonal or psychoactive medication effects did not compromise 
results, all analyses were repeated excluding seven participants using the 
following agents: one male for finasteride (an antiandrogen), one female for 
estradiol, one female for gabapentin, and four females and one male for opiates. 
The overall pattern of results was unchanged after these exclusions. No 
participants were using antidepressants, anxiolytics, or antipsychotics.  
 
The minor allele frequency was 0.46 for the rs2234693C allele and 0.34 for the 
rs9340799 G allele. Linkage disequilibrium (LD) analysis for the two SNPs 
indicated high values of r2=0.741 and D’=1.00, and the CG and TA haplotypes 
were in phase (i.e., the two alleles are inherited together more frequently than 
expected under linkage equilibrium). 
 
Gray Matter Density and Cortical Thickness 
VBM results from rs9340799 will be discussed here, as genotype effects were 
stronger for this SNP. As expected, since the SNPs are in strong LD, the pattern 
of results was similar for rs2234693 (not shown). rs9340799 genotype had 
differential effects on GM density by sex: in a sex by genotype interaction, males 
carrying a major allele (A) and females carrying a minor allele (G) showed areas 
of increased GM density (Figure 3-1), including bilateral frontal, parietal, and 
temporal regions (Table 3-2). This “increased GM density in carriers” was the 
best fit of several models, including comparing homozygotes only (i.e., AA>GG 
and GG>AA) or increased density in homozygotes (i.e., AA>GA, GG and 
GG>GA, AA) (data not shown). Single-sex comparisons revealed that, in general, 
these effects were more prominent in frontal regions in males and parietal 
regions in females. The opposite contrasts (greater GM density in males carrying 
a G or in females carrying an A) did not show significant clusters. Cortical 
thickness analysis using these contrasts revealed similarly distributed results 
(Figure 3-1), although the female-only contrast did not show any significant 
clusters. 
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Figure 3-1 Surface renderings of statistically significant clusters in a voxel-based 
morphometry analysis of gray matter density (left) or a SurfStat analysis of 
cortical thickness (right) for rs9340799. Clusters significant in a genotype-by-sex 
interaction are shown in the top row, with clusters from both within-sex 
components of that interaction below. For gray matter density, voxel-level pcrit 
was set to 0.005 and a minimum cluster extent of k=1900 was used to retain only 
clusters with puncorrected ≤0.05. For cortical thickness, a Random Field Theory 
correction method was used at a 0.05 significance level.  
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Table 3-2 Description of statistically significant clusters derived from voxel-based 
morphometry omnibus ANOVA including factors of ESR1 rs9340799 genotype 
and sex. Clusters significant in a genotype-by-sex interaction are listed first, 
followed by clusters from both within-sex components of that interaction. Voxel-
level pcrit was set to 0.005 and a minimum cluster extent of k=1900 was used to 
retain only clusters with puncorrected ≤0.05. (No significant clusters were found 
using the opposite interaction or its within-sex components.) 
 
 
Peak MNI 
coordinates 
(x y z) 
Cluster 
extent 
 (k) 
Cluster-
level 
pcorrected 
Cluster-
level 
puncorrected 
Peak 
voxel-
level  
puncorrected 
T Region description of local 
maxima within cluster 
 
Brodmann 
Areas 
rs9340799 Interaction: Males AA, GA>GG; Females GG, GA>AA 
38 -35 -24 20498 <0.001 <0.001 <0.001 4.52 Right fusiform and inferior 
temporal gyri 
19,20 
-8 -56 -17 9186 0.006 <0.001 <0.001 3.96 Left cerebellum, left 
parahippocampal and right 
posterior cingulate gyri 
30,36 
-26 48 23 6937 0.023 0.001 <0.001 3.92 Left superior and middle 
frontal gyri 
10, 46 
20 54 24 1926 0.688 0.054 <0.001 3.89 Right superior frontal gyrus 10 
-62 -25 39 4125 0.156 0.008 <0.001 3.83 Left postcentral gyrus and 
inferior parietal lobule 
2, 40 
28 -55 58 2308 0.551 0.037 <0.001 3.65 Right superior parietal lobule 
and precuneus 
7 
-35 -74 38 6590 0.028 0.001 <0.001 3.62 Left precuneus and 
postcentral gyrus 
2, 5, 19 
-12 -79 0 4480 0.121 0.006 <0.001 3.60 Left lingual and middle 
occipital gyri 
18 
37 -69 40 3270 0.288 0.016 <0.001 3.38 Right precuneus, inferior 
parietal and middle temporal 
gyri 
19,39,40 
rs9340799: Males AA, GA>GG 
51 -21 -13 4181 0.150 0.008 <0.001 4.40 Right superior, middle, and 
inferior temporal gyri 
20, 21, 22 
-34 -8 -6 2157 0.604 0.043 <0.001 4.26 Left claustrum N/A 
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20 53 25 6130 0.038 0.002 <0.001 3.92 Right superior and medial 
frontal gyri 
8, 10 
-23 47 23 5200 0.073 0.004 <0.001 3.86 Left superior and middle 
frontal gyri 
8, 9, 10 
35 -60 -37 7181 0.019 0.001 <0.001 3.76 Right cerebellum N/A 
-7 30 44 2140 0.610 0.044 <0.001 3.60 Left medial and superior 
frontal gyri 
8 
-34 -50 -42 2081 0.631 0.046 <0.001 3.43 Left cerebellum N/A 
rs9340799: Females GG, GA>AA 
-21 -61 62 7376 0.017 0.001 <0.001 4.23 Left superior parietal lobule 
and postcentral gyrus 
5, 7 
37 -37 -24 4167 0.151 0.008 <0.001 3.88 Right fusiform gyrus and 
cerebellum 
20 
-24 -34 -15 2348 0.538 0.036 <0.001 3.87 Left parahippocampal gyrus 
and cerebellum 
36 
22 -62 63 6993 0.022 0.001 <0.001 3.69 Right postcentral gyrus and 
superior and inferior parietal 
lobules 
5, 7, 40 
-57 -41 40 2929 0.366 0.021 <0.001 3.65 Left inferior parietal lobule 
and superior temporal gyrus 
22, 40 
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Using mean GM density values from clusters in the male-only VBM contrast, the 
variance accounted for by rs9340799 genotype (classified as 0, 1, or 2 minor 
alleles) ranged from 4-17%. Analyses in the female-only contrast showed that 
genotype accounted for 11-19% of variance.  
 
Multivariate general linear models did not indicate epistasis between ESR1 
genotype and APOE-ε4 carrier status (i.e., no ESR1 by APOE interactions) for 
any cluster from either sex-specific contrast for either SNP. 
 
MTL Volumetry 
Figure 3-2 shows group mean values for hippocampus and amygdala volumes. 
Similar to VBM analyses, significant genotype associations with volume were 
observed for rs9340799 but not rs2234693. In females a significant effect of 
rs9340799 genotype was found for the left amygdala (p=0.025). A post-hoc 
Tukey test revealed that female participants with a GG genotype showed greater 
volumes than those with an AA genotype (p≤0.05). Trend level results following 
the same pattern were seen for females for the right amygdala (p=0.057) and left 
hippocampus (p=0.056). In general, there was an overall pattern across sexes, 
structures, and SNPs of association of the minor allele with higher volumes. 
74 
Figure 3-2 Mean age- and intracranial volume-adjusted bilateral hippocampus 
and amygdala volumes separated by sex and genotype for both rs2234693 (left 
column) and rs9340799 (right column). Bars represent mean ±SEM.*: p<0.05 in 
one-way ANOVA by genotype within gender. †: p<0.06 in one-way ANOVA by 
genotype within gender. 
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In structures with statistically significant or trend-level genotype effects (left 
amygdala, left hippocampus, and right amygdala volumes for rs9340799 in 
females) genotype accounted for 9.1%, 1.5%, and 6.5% of variance, 
respectively.  
 
Epistasis between ESR1 rs2234693 genotype and APOE-ε4 allele (i.e., ESR1 
genotype by APOE carrier status interaction) was observed for females but not 
males in both left (p=0.035) and right (p=0.017) amygdalae (Figure 3-3) Post-hoc 
t-tests revealed that in females of the rs2234693 TT genotype, but not CT or CC, 
APOE-ε4 carriers had significantly lower left (p=0.029) and right (p=0.005) 
amygdala volumes. For rs9340799 no interactions with APOE status were 
evident. 
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Figure 3-3 ESR1 rs2234693 genotype by APOE-ε4 carrier status interaction in 
bilateral amygdala in women. Multivariate ANOVA with factors of rs2234963 
genotype and APOE-ε4 status showed significant interaction (p≤0.05); asterisks 
represent p≤0.05 between APOE-ε4 carriers and non-carriers in post-hoc t-tests. 
Bars represent mean ±SEM. TT genotype n=22 (27% APOE- ε4 carriers), CT 
genotype n=47 (32% APOE- ε4 carriers), and CC genotype n=21 (19% APOE- 
ε4 carriers).  
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Discussion 
This study is the first to demonstrate that genetic variation in ESR1 has widely 
distributed effects on brain structure that differ by both sex and brain region. In 
our examination of 195 cognitively and psychiatrically normal older adults, there 
was greater GM density in regions throughout the brain in males carrying an 
rs9340799 A allele or an rs2234693 T allele (major alleles), while in contrast, GM 
density was greater in females carrying an rs9340799 G allele or an rs2234693 C 
allele (minor alleles). These effects on GM were not modulated by APOE-ε4 
carrier status. Cortical thickness analyses showed similarly distributed results. 
We found in females that left amygdala volume, was significantly associated with 
rs9340799 genotype, with similar trends for right amygdala and left hippocampus 
volumes. Higher volumes in both sexes were observed with the GG genotype 
compared to AA the left amygdala, with consistent patterns of greater MTL 
volumes associated with minor alleles. These MTL volumetry findings are 
consistent with a previous study [190] in which women, but not men, with 
homozygous minor allele (CC or GG) genotypes showed increased amygdala 
volumes. Finally, APOE-ε4 carrier status modulated the effect of rs2234693 on 
amygdala volumes in women, with low volumes in APOE-ε4 carriers compared to 
non-APOE-ε4 carriers in the TT genotype only. This evidence of epistasis 
between APOE and ESR1 in influencing brain structure has not been reported 
previously.  
 
Sexual dimorphisms are well-documented in prevalence and presentation of 
many psychiatric and neurological disorders. While the neuropathophysiological 
mechanisms underlying these differences remain poorly understood, sex 
hormone signaling is thought to play an important role. This study is the first to 
demonstrate that, even in cognitively and psychiatrically healthy older adults, 
genetic variation in estrogen signaling widely affects brain morphology in ways 
that differ by sex and brain region. Notably, the affected areas observed in the 
present report, including MTL and prefrontal cortex, have been implicated in 
many psychiatric and neurological disorders. Our results document a differential 
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pattern of estrogen influence on brain morphology. In turn, this suggests that 
estrogen signaling is an important pathway in the study of sex differences in such 
disorders. An estrogen-dependent mechanism for the reported ESR1-associated 
morphological changes is highly plausible based on two areas of consistency 
with previous literature. First, the affected regions (hippocampus, amygdala, and 
distributed cortical areas [207], including the prefrontal cortex [208]), have been 
shown to express ER-α in both male and female humans and/or non-human 
primates, with the amygdala being particularly rich in ER-α expression [209]. Our 
volumetric results are also consistent with previously described ER-α expression 
patterns in showing greater ESR1 effects in amygdala compared to 
hippocampus. Second, the brain regions associated with ESR1 genotype in this 
report have been demonstrated to be estrogen-responsive in human structural 
neuroimaging studies, with higher-estrogen states generally associated with 
greater GM density in women of the same age. Specifically, when results are 
combined across studies comparing postmenopausal women using and not 
using hormone replacement therapy [81-85, 210], premenopausal women across 
various stages of the menstrual cycle [211, 212], and premenopausal women 
using and not using hormonal contraceptives [212], a total of 15 brain regions 
have been demonstrated to be estrogen-sensitive. Of these 15, 11 were found in 
our study, including prefrontal cortex, medial frontal gyrus, postcentral gyrus, 
fusiform, lingual, and parahippocampal gyri, hippocampus, inferior, middle, and 
superior temporal gyri, basal ganglia, and cerebellum. Overall, the considerable 
regional overlap of our results with previously described ER-α expression 
patterns and estrogen-sensitive regions is consistent with an estrogen-dependent 
mechanism for ESR1-related morphological differences, rather than ESR1 
variation serving as a proxy for some other unrelated marker. 
 
The interaction by which genetic variation in ESR1 is associated with opposite 
effects on GM density between sexes is particularly interesting. In the current 
study, the C and G minor alleles of the respective SNPs were associated with 
both greater MTL volumes in females (with similar patterns in males), The minor 
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C and G minor alleles was also associated with greater cortical GM density in 
females and decreased cortical GM density in males. Thus, the same ESR1 
genotype is associated with greater density/ volume of MTL in both sexes and 
cortex in females, with the opposite effect in male cortex. Supporting preclinical 
evidence suggests that estrogen exposure may differentially affect brain regions 
by sex at the cellular level: in adult female rats, exposure to estrogen increases 
spine synapses in both hippocampus and prefrontal cortex, whereas estrogen 
exposure in adult male rats increases spine synapses in prefrontal cortex but not 
hippocampus (for review, see [51]).  
 
Numerous studies have identified the C and G minor alleles as risk factors for 
neurological or psychiatric disorders. However, the studies are conflicting and it 
is not clear how ethnicity and gender may modulate these effects [70]. In a meta-
analysis of AD genetic association studies, Bertram and colleagues found that 
the C and G alleles are associated with AD, with odds ratios of ~1.2 [185]. 
Sundermann and colleagues found in a recent review that 8 of 18 studies 
identified C and G alleles as risk factors for cognitive impairment, and 2 of 4 
studies identified C and G as risk alleles for mood and anxiety disorders [70]. 
Weickert et al. [184] found overtransmission of the C allele in schizophrenia 
patients. The association of the C and G “risk” alleles with lower GM density in 
men observed in the current report is consistent with these previous studies. 
Further, the association of the G “risk” genotype with greater amygdala volumes 
in women is interesting in light of evidence for greater amygdala volumes in 
depressed patients [213]. It should be noted that the greater cortical GM density 
in women with the “risk” alleles may be related to the postmenopausal status and 
lack of current hormone replacement therapy in the study population, or to other 
factors. Future work will be necessary to comprehensively identify ESR1 
genotype-by-sex interactions in the substrates of neurological and psychiatric 
disorders. 
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The mechanism by which rs2234693 and rs9340799 affect neural estrogen 
signaling is unclear. In the brain, estrogen acts at both organizational 
(developmental) and activational (exposure later in life) levels; genetic variation 
in ER-α could influence both. In vitro results suggest that the C but not T 
genotype of rs2234693 allows binding of the transcription factor b-Myb to the ER-
α protein, with unknown effects on transcriptional activity [214]. Human B-cells 
with CC or GG genotypes show increased ESR1 mRNA [183]. However, in 
another study the T allele appeared to be associated with increased ESR1 
enhancer activity, possibly indicating increased transcription [215]. Clinically, the 
C allele of rs2234693 and the G allele of rs9340799 have been associated with 
increased serum estradiol in postmenopausal women [216], with no association 
between these SNPs and serum estrogen or testosterone in older men [216, 
217]. Weickert and colleagues observed that in schizophrenia patients, but not 
controls, the C allele of rs2234693 was associated with decreased ESR1 mRNA 
in the frontal cortex [184]. Overall, it appears that variation in these SNPs may 
alter estrogen signaling via a complex interplay among ER-α expression, ER-α 
downstream activity, and feedback mechanisms regulating estrogen synthesis. 
These processes may vary by sex, age, and disease state, making evaluation of 
the underlying pathways difficult 
 
APOE-ε4 allele may interact with ESR1 to influence dementia onset [71-73], and 
our results suggest a possible neural basis for this interaction. rs2234693 
significantly interacted with APOE-ε4 carrier status in bilateral amygdalae in 
females, with APOE-ε4 positive women in the TT (lowest amygdala volume) 
group showing lower volumes relative to APOE-ε4 negative women. It may be 
that women carrying a C allele were protected from APOE-ε4 -associated deficits 
in amygdala volume. Biologically, there is evidence that the APOE protein is 
important in the pathway by which estrogen exerts its neuroprotective effects; 
these effects are disrupted by the presence of APOE-ε4 protein [178]. 
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Several aspects of this study have notable strengths. Spurious results due to 
population stratification are unlikely, as only non-Hispanic Caucasian participants 
were included. The allele frequencies for rs2234693 and rs9340799 were similar 
to those in other studies [190] and those in the HapMap CEU population in 
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/). Additionally, our imaging 
methods were completely automated and therefore free from potential 
investigator-introduced bias. The fact that we showed similar outcomes using 
VBM and cortical thickness measures add confidence that methodological 
artifacts do not account for the reported effects. Finally, regression analyses 
showed that substantial proportions of variance in brain phenotypes (up to 19%) 
were accounted for by ESR1 genotype, increasing the likelihood of these effects’ 
potential functional significance. 
 
There are several limitations to this study. First, our sample was comprised of 
non-Hispanic Caucasian participants, so the results may not generalize to other 
ethnic and racial groups. Indeed, there is evidence that ESR1 genotype may 
differentially influence cognitive decline by ethnicity [70]. Second, females in our 
study were postmenopausal, and, likely had been for some time. While only one 
participant was using hormone replacement therapy at the time of the study, the 
hormonal treatment history of this sample is unknown. With the neural benefits 
(and likely structural brain effects) of hormonal therapy depending on both timing 
and formulation of therapy [59, 60], hormonal treatment history would provide 
valuable information. Treatment history should be considered in future studies 
designed specifically to test the neural effects of variation in estrogen pathway 
genes. 
 
To determine how ESR1 might modulate neurodegeneration, future work will 
examine the neural correlates of rs2234693 and rs9340799 in MCI and AD 
populations, Additional studies will be needed to address the effects of ESR1 in 
diverse populations, e.g., psychiatric patients and younger people. Functional 
imaging studies may help address how structural changes might influence clinical 
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and behavioral phenotypes. Finally, other estrogen-related genes, such as ESR2 
(coding for ER-β) and CYP19A1 (aromatase) should be studied. Understanding 
the mechanisms by which alterations in estrogen signaling affect the brain may 
provide insight into potential etiologies or treatments for the numerous sexually 
dimorphic psychiatric and neurological disorders.  
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Summary 
In summary, Chapter 1 showed that cognitive complaints and oxidative DNA 
damage were increased, and memory performance decreased, in BC survivors 
compared to HC. Imaging results indicated lower gray matter density (GMD) and 
fMRI activation in several regions in the BC survivor group. PCI was associated 
with both GMD and activation in the right frontal lobe independent of participant 
age. GMD in this region was also correlated with global neuropsychological 
function. In regions where BCS showed decreased GMD this was inversely 
related to oxidative DNA damage and learning and memory neuropsychological 
domain scores. This was the first study to show structural and functional effects 
of PCI, and also the first to relate DNA damage to brain alterations in BCS. The 
relationship between neuroimaging and cognitive function suggests that these 
findings have potential clinical relevance. The relationship with peripheral 
oxidative DNA damage provides a mechanistic clue that warrants further 
investigation regarding the relationships among cancer- and treatment-related 
oxidative stress, brain structural changes, and cognition.  
 
The functional brain effects of chemotherapy-induced amenorrhea (CIA) were 
explored in Chapter 2. We found that combined magnitudes of brain activation 
and deactivation decreased from pre-to post-chemotherapy in patients 
undergoing CIA compared to both postmenopausal BC patients undergoing 
chemotherapy and healthy controls. Furthermore, the change in brain activity 
magnitude in CIA was strongly correlated with change in processing speed, 
suggesting this increase in brain activity reflects adaptive cognitive 
compensation. Our results also demonstrate that the pattern of change in brain 
activity from pre- to post-chemotherapy varies according to pre-treatment 
menopausal status. Cognitive correlates add to the potential clinical significance 
of these findings. These findings have implications for risk appraisal and 
development of prevention or treatment strategies for cognitive changes in CIA.  
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In Chapter 3, genetic variation in ESR1, the gene coding for estrogen receptor-α, 
was found to influence hippocampal and amygdalar volumes, particularly in 
females. The single nucleotide polymorphism rs9340799 influenced cortical gray 
matter density and cortical thickness differentially by gender. Finally, APOE-ε4 
carrier status modulated the effect of rs2234693 on amygdala volumes in 
women; this evidence of epistasis between APOE and ESR1 in influencing brain 
structure has not been reported previously. This study is the first to demonstrate 
that, even in cognitively and psychiatrically normal older adults, genetic variation 
in estrogen signaling widely affects brain morphology in ways that differ by sex, 
brain region and APOE-ε4 carrier status.  
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Future Directions  
To more completely understand the relationship among BC, its treatments, and 
cognition, several aspects that are missing from the literature should be better 
studied. To better establish the time course of cognitive and neural changes, 
patients must be studied prospectively over longer post-treatment intervals—from 
pre-treatment through years into survivorship. Retrospective studies such as 
Chapter 1 provide clues, but definitive time course information can only be 
gleaned from longitudinal studies. The neural effects of tamoxifen and aromatase 
inhibitors will be crucial factors as well, and should be systematically studied. 
Currently use of these agents is often treated as a confound due to the focus on 
chemotherapy and the variability in hormonal treatment regimens. Other cancer 
treatments, such as antiangiogenic agents, targeted therapies, and immune 
modulators, are now widely used. The molecular targets of many of these agents 
are also relevant to brain function, so studying their effectsin future studies will be 
critical. 
 
Since neuroimaging studies of BC patients must be observational rather than 
controlled experiments, there are many potential confounds (antidepressant use, 
smoking status, hypertension, etc.) that affect dependent measures such as 
BOLD fMRI. Studying a wide range of BC patients and not just a carefully 
selected group is important for generalizability of results. Sophisticated statistical 
modeling techniques, such as independent component analysis and 
nonparametric tests, could be applied to try to differentiate all of these influences. 
This modeling would be helpful in ascertaining the effects of specific 
chemotherapy regimens and hormonal treatments and would maximize use of 
collected data, which is important because these studies are expensive for 
researchers and burdensome for patients. Choosing the dependent variables, 
i.e., specific cognitive and neural phenotypes, that are most sensitive to cancer- 
and treatment-related cognitive dysfunction will be important in this context. 
Studies such as those in Chapters 1 and 2 contribute to this effort. 
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Because cancer- and treatment-related changes assessed by neuropsychology 
and neuroimaging are rather subtle, much larger cohorts than those in the 
present report will be required to have adequate power to detect and fully 
characterize these changes. To accomplish this, multicenter collaborations will 
be critical as it is clear in the current literature that recruitment at a single cancer 
center cannot provide the hundreds of patients needed for such studies. 
Recruitment and retention are important in this effort, so utmost care should be 
taken to maximize efficiency in data gathering and minimize patient burden. This 
will involve difficult choices regarding which measures to collect. Large cohorts 
will also allow for meaningful genetic studies which could provide clues to one of 
the more perplexing (and important) questions in the field: why is only a subset of 
patients affected by cancer- and treatment-related cognitive dysfunction?  
 
Further study of the biological mechanisms of cancer- and treatment-related 
cognitive dysfunction is critical for development of neuroprotective, therapeutic, 
or rehabilitative interventions. Our finding of increased peripheral oxidative 
damage related to gray matter changes in survivors contributes to this 
burgeoning field. Systemic inflammation and direct neurotoxicity are thought to 
damage areas of the brain where neurogenesis occurs, and it is hypothesized 
that this is part of the pathology underlying cognitive dysfunction [218]. Animal 
and human studies are needed to explore this hypothesis further. Cognitive 
dysfunction is part of a constellation of sequelae in cancer patients that includes 
sleep dysfunction, fatigue, anxiety, and depression, among others. All of these 
problems are intertwined with the neuroendocrine (i.e., cortisol changes) and 
immune (including systemic inflammation) disruptions that are known to occur in 
cancer patients. It will be important for researchers in these disparate fields to 
collaborate in order to establish a fuller picture of the subjective distress in many 
areas of life experienced by cancer patients. 
 
Evidence for the efficacy of multiple types of interventions, medical and 
behavioral, is emerging (see [219] for review). Pharmacologic treatments, 
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including methylphenidate [220] and fluoxetine [221] show some promise in initial 
studies. In rodents (but so far not in humans), exercise has been shown to 
alleviate cognitive dysfunction after chemotherapy [222]. As previously 
discussed, decreases in estrogen function appear to contribute to cognitive 
dysfunction in BC. A promising target for drug development is the “neuro-SERM” 
which would act as an estrogen agonist in brain and bone (to prevent 
osteoporosis) while being anti-estrogen to breast and uterine tissue to prevent 
reoccurrence and other malignancy [127, 172]. A “neuro-SERM” is also an 
attractive option for chemoprevention in women at high risk for BC. All of these 
interventions are in early stages of study but show promise to help patients in the 
future. 
 
Further understanding of estrogen’s role in the human brain will contribute to 
knowledge of BC but is also applicable more generally. Our unexpected finding 
of an interaction of gender with ESR1 genotype with regard to cortical gray 
matter as described in Chapter 3 warrants replication in an independent cohort, 
which is currently underway. Further, more sophisticated genetic analyses than 
those employed here will also be helpful: gene-based or pathway analysis, for 
example, would allow study of genetic variation at multiple points in the estrogen 
synthetic, response, and degradation pathways using the same number of 
subjects. This approach utilizes more of the rich genetic dataset available from a 
genome-wide assay. Pathway analysis also lacks the limitation of dividing 
participants into discrete genetic groups, which can be problematic given that 
many influential SNPs have low minor allele frequencies. 
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Conclusions 
In conclusion, this document explored the interplay of breast cancer, estrogen, 
and cognition using human neuroimaging and genetic methods. The results 
showed that post-chemotherapy interval, chemotherapy-induced amenorrhea, 
and genetic variation in an estrogen receptor all influence brain phenotypes. 
Cognitive correlates of brain findings add to the potential clinical significance of 
the results. This work provides novel insights into the neural effects of breast 
cancer treatment. It is hoped that these results inform future research into 
neuroprotective or therapeutic interventions to preserve brain function in cancer 
patients as well as those who experience decreases in systemic estrogen. 
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